English
Segment disclosures
Company overviewAmneal Pharmaceuticals, Inc.
Each reported dimension combination stays separate. Revenue and operating income are shown as reported, with their dates and sources.
Revenue · Reported segment facts
Counts describe retained dimensioned rows only. Periods and members can change across reports, and this view does not infer missing values or expected segment totals.
Operating Segments · Affordable Medicines Segment
Consolidation Items · Statement Business Segments
Source dimensions
srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=amrx:AffordableMedicinesSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-04-01 – 2026-06-30 | 489913000 | USD | 20260806 | Open filing evidence |
| 2026-01-01 – 2026-06-30 | 913150000 | USD | 20260806 | Open filing evidence |
| 2026-01-01 – 2026-03-31 | 423237000 | USD | 20260507 | Open filing evidence |
| 2025-01-01 – 2025-12-31 | 1745524000 | USD | 20260227 | Open filing evidence |
| 2025-07-01 – 2025-09-30 | 460741000 | USD | 20251106 | Open filing evidence |
| 2025-01-01 – 2025-09-30 | 1308874000 | USD | 20251106 | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 433425000 | USD | 20260806 | Open filing evidence |
| 2025-01-01 – 2025-06-30 | 848133000 | USD | 20260806 | Open filing evidence |
| 2025-01-01 – 2025-03-31 | 414708000 | USD | 20260507 | Open filing evidence |
| 2024-01-01 – 2024-12-31 | 1685263000 | USD | 20260227 | Open filing evidence |
| 2024-07-01 – 2024-09-30 | 427345000 | USD | 20251106 | Open filing evidence |
| 2024-01-01 – 2024-09-30 | 1245967000 | USD | 20251106 | Open filing evidence |
| 2024-04-01 – 2024-06-30 | 427328000 | USD | 20250807 | Open filing evidence |
| 2024-01-01 – 2024-06-30 | 818622000 | USD | 20250807 | Open filing evidence |
| 2024-01-01 – 2024-03-31 | 391294000 | USD | 20250507 | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 1471401000 | USD | 20260227 | Open filing evidence |
Operating Segments · Amneal Specialty Pharma Segment
Consolidation Items · Statement Business Segments
Source dimensions
srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=amrx:AmnealSpecialtyPharmaSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-04-01 – 2026-06-30 | 149295000 | USD | 20260806 | Open filing evidence |
| 2026-01-01 – 2026-06-30 | 282560000 | USD | 20260806 | Open filing evidence |
| 2026-01-01 – 2026-03-31 | 133265000 | USD | 20260507 | Open filing evidence |
| 2025-07-01 – 2025-09-30 | 125240000 | USD | 20251106 | Open filing evidence |
| 2025-01-01 – 2025-09-30 | 361580000 | USD | 20251106 | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 128043000 | USD | 20260806 | Open filing evidence |
| 2025-01-01 – 2025-06-30 | 236340000 | USD | 20260806 | Open filing evidence |
| 2025-01-01 – 2025-03-31 | 108297000 | USD | 20260507 | Open filing evidence |
| 2024-07-01 – 2024-09-30 | 115638000 | USD | 20251106 | Open filing evidence |
| 2024-01-01 – 2024-09-30 | 324913000 | USD | 20251106 | Open filing evidence |
| 2024-04-01 – 2024-06-30 | 104041000 | USD | 20250807 | Open filing evidence |
| 2024-01-01 – 2024-06-30 | 209275000 | USD | 20250807 | Open filing evidence |
| 2024-01-01 – 2024-03-31 | 105234000 | USD | 20250507 | Open filing evidence |
| 2023-07-01 – 2023-09-30 | 97304000 | USD | 20241112 | Open filing evidence |
| 2023-01-01 – 2023-09-30 | 285976000 | USD | 20241112 | Open filing evidence |
Operating Segments · Av KARE Segment
Consolidation Items · Statement Business Segments
Source dimensions
srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=amrx:AvKARESegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-04-01 – 2026-06-30 | 156989000 | USD | 20260806 | Open filing evidence |
| 2026-01-01 – 2026-06-30 | 323006000 | USD | 20260806 | Open filing evidence |
| 2026-01-01 – 2026-03-31 | 166017000 | USD | 20260507 | Open filing evidence |
| 2025-01-01 – 2025-12-31 | 744728000 | USD | 20260227 | Open filing evidence |
| 2025-07-01 – 2025-09-30 | 198532000 | USD | 20251106 | Open filing evidence |
| 2025-01-01 – 2025-09-30 | 533987000 | USD | 20251106 | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 163040000 | USD | 20260806 | Open filing evidence |
| 2025-01-01 – 2025-06-30 | 335455000 | USD | 20260806 | Open filing evidence |
| 2025-01-01 – 2025-03-31 | 172415000 | USD | 20260507 | Open filing evidence |
| 2024-01-01 – 2024-12-31 | 662945000 | USD | 20260227 | Open filing evidence |
| 2024-07-01 – 2024-09-30 | 159485000 | USD | 20251106 | Open filing evidence |
| 2024-01-01 – 2024-09-30 | 492559000 | USD | 20251106 | Open filing evidence |
| 2024-04-01 – 2024-06-30 | 170411000 | USD | 20250807 | Open filing evidence |
| 2024-01-01 – 2024-06-30 | 333074000 | USD | 20250807 | Open filing evidence |
| 2024-01-01 – 2024-03-31 | 162663000 | USD | 20250507 | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 531749000 | USD | 20260227 | Open filing evidence |
| 2023-07-01 – 2023-09-30 | 131879000 | USD | 20241112 | Open filing evidence |
| 2023-01-01 – 2023-09-30 | 382286000 | USD | 20241112 | Open filing evidence |
Operating Segments · Generics Segment
Consolidation Items · Statement Business Segments
Source dimensions
srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=amrx:GenericsSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2024-07-01 – 2024-09-30 | 427345000 | USD | 20241112 | Open filing evidence |
| 2024-01-01 – 2024-09-30 | 1245967000 | USD | 20241112 | Open filing evidence |
| 2024-04-01 – 2024-06-30 | 427328000 | USD | 20240809 | Open filing evidence |
| 2024-01-01 – 2024-06-30 | 818622000 | USD | 20240809 | Open filing evidence |
| 2024-01-01 – 2024-03-31 | 391294000 | USD | 20240508 | Open filing evidence |
| 2023-07-01 – 2023-09-30 | 390857000 | USD | 20241112 | Open filing evidence |
| 2023-01-01 – 2023-09-30 | 1108364000 | USD | 20241112 | Open filing evidence |
Operating Segments · Specialty Segment
Consolidation Items · Statement Business Segments
Source dimensions
srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=amrx:SpecialtySegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2025-01-01 – 2025-12-31 | 528508000 | USD | 20260227 | Open filing evidence |
| 2024-01-01 – 2024-12-31 | 445749000 | USD | 20260227 | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 390457000 | USD | 20260227 | Open filing evidence |
Antiviral · Generics Segment · US
Product Or Service · Statement Business Segments · Statement Geographical
Source dimensions
srt:ProductOrServiceAxis=amrx:AntiviralMember;us-gaap:StatementBusinessSegmentsAxis=amrx:GenericsSegmentMember;srt:StatementGeographicalAxis=country:US| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2023-07-01 – 2023-09-30 | 7150000 | USD | 20231109 | Open filing evidence |
| 2023-01-01 – 2023-09-30 | 36221000 | USD | 20231109 | Open filing evidence |
Biosimilar · US · Affordable Medicines Segment
Product Or Service · Statement Geographical · Statement Business Segments
Source dimensions
srt:ProductOrServiceAxis=amrx:BiosimilarMember;srt:StatementGeographicalAxis=country:US;us-gaap:StatementBusinessSegmentsAxis=amrx:AffordableMedicinesSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2025-01-01 – 2025-12-31 | 100228000 | USD | 20260227 | Open filing evidence |
| 2025-07-01 – 2025-09-30 | 17009000 | USD | 20251106 | Open filing evidence |
| 2025-01-01 – 2025-09-30 | 70797000 | USD | 20251106 | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 25248000 | USD | 20250807 | Open filing evidence |
| 2025-01-01 – 2025-06-30 | 53788000 | USD | 20250807 | Open filing evidence |
| 2024-01-01 – 2024-12-31 | 125422000 | USD | 20260227 | Open filing evidence |
| 2024-07-01 – 2024-09-30 | 30678000 | USD | 20251106 | Open filing evidence |
| 2024-01-01 – 2024-09-30 | 86870000 | USD | 20251106 | Open filing evidence |
| 2024-04-01 – 2024-06-30 | 29500000 | USD | 20250807 | Open filing evidence |
| 2024-01-01 – 2024-06-30 | 56192000 | USD | 20250807 | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 65923000 | USD | 20260227 | Open filing evidence |
Biosimilar · Affordable Medicines Segment
Product Or Service · Statement Business Segments
Source dimensions
srt:ProductOrServiceAxis=amrx:BiosimilarMember;us-gaap:StatementBusinessSegmentsAxis=amrx:AffordableMedicinesSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-04-01 – 2026-06-30 | 29128000 | USD | 20260806 | Open filing evidence |
| 2026-01-01 – 2026-06-30 | 51429000 | USD | 20260806 | Open filing evidence |
| 2026-01-01 – 2026-03-31 | 22301000 | USD | 20260507 | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 25248000 | USD | 20260806 | Open filing evidence |
| 2025-01-01 – 2025-06-30 | 53788000 | USD | 20260806 | Open filing evidence |
| 2025-01-01 – 2025-03-31 | 28540000 | USD | 20260507 | Open filing evidence |
Cardiovascular System · Generics Segment · US
Product Or Service · Statement Business Segments · Statement Geographical
Source dimensions
srt:ProductOrServiceAxis=amrx:CardiovascularSystemMember;us-gaap:StatementBusinessSegmentsAxis=amrx:GenericsSegmentMember;srt:StatementGeographicalAxis=country:US| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2023-07-01 – 2023-09-30 | 32459000 | USD | 20231109 | Open filing evidence |
| 2023-01-01 – 2023-09-30 | 98108000 | USD | 20231109 | Open filing evidence |
Central Nervous System · US · Specialty Segment
Product Or Service · Statement Geographical · Statement Business Segments
Source dimensions
srt:ProductOrServiceAxis=amrx:CentralNervousSystemMember;srt:StatementGeographicalAxis=country:US;us-gaap:StatementBusinessSegmentsAxis=amrx:SpecialtySegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2025-01-01 – 2025-12-31 | 333417000 | USD | 20260227 | Open filing evidence |
| 2025-07-01 – 2025-09-30 | 77631000 | USD | 20251106 | Open filing evidence |
| 2025-01-01 – 2025-09-30 | 228666000 | USD | 20251106 | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 83425000 | USD | 20250807 | Open filing evidence |
| 2025-01-01 – 2025-06-30 | 151035000 | USD | 20250807 | Open filing evidence |
| 2024-01-01 – 2024-12-31 | 280174000 | USD | 20260227 | Open filing evidence |
| 2024-07-01 – 2024-09-30 | 73401000 | USD | 20251106 | Open filing evidence |
| 2024-01-01 – 2024-09-30 | 203583000 | USD | 20251106 | Open filing evidence |
| 2024-04-01 – 2024-06-30 | 63906000 | USD | 20250807 | Open filing evidence |
| 2024-01-01 – 2024-06-30 | 130182000 | USD | 20250807 | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 249981000 | USD | 20260227 | Open filing evidence |
Central Nervous System · Specialty Segment
Product Or Service · Statement Business Segments
Source dimensions
srt:ProductOrServiceAxis=amrx:CentralNervousSystemMember;us-gaap:StatementBusinessSegmentsAxis=amrx:SpecialtySegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-04-01 – 2026-06-30 | 95344000 | USD | 20260806 | Open filing evidence |
| 2026-01-01 – 2026-06-30 | 178727000 | USD | 20260806 | Open filing evidence |
| 2026-01-01 – 2026-03-31 | 83383000 | USD | 20260507 | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 83425000 | USD | 20260806 | Open filing evidence |
| 2025-01-01 – 2025-06-30 | 151035000 | USD | 20260806 | Open filing evidence |
| 2025-01-01 – 2025-03-31 | 67610000 | USD | 20260507 | Open filing evidence |
Ephinephrine Auto Injector · US · Affordable Medicines Segment
Product Or Service · Statement Geographical · Statement Business Segments
Source dimensions
srt:ProductOrServiceAxis=amrx:EphinephrineAutoInjectorMember;srt:StatementGeographicalAxis=country:US;us-gaap:StatementBusinessSegmentsAxis=amrx:AffordableMedicinesSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2025-01-01 – 2025-12-31 | 232796000 | USD | 20260227 | Open filing evidence |
| 2025-07-01 – 2025-09-30 | 78940000 | USD | 20251106 | Open filing evidence |
| 2025-01-01 – 2025-09-30 | 193694000 | USD | 20251106 | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 66594000 | USD | 20250807 | Open filing evidence |
| 2025-01-01 – 2025-06-30 | 114754000 | USD | 20250807 | Open filing evidence |
| 2024-01-01 – 2024-12-31 | 209497000 | USD | 20260227 | Open filing evidence |
| 2024-07-01 – 2024-09-30 | 70690000 | USD | 20251106 | Open filing evidence |
| 2024-01-01 – 2024-09-30 | 171589000 | USD | 20251106 | Open filing evidence |
| 2024-04-01 – 2024-06-30 | 58281000 | USD | 20250807 | Open filing evidence |
| 2024-01-01 – 2024-06-30 | 100899000 | USD | 20250807 | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 160853000 | USD | 20260227 | Open filing evidence |
Ephinephrine Auto Injector · Affordable Medicines Segment
Product Or Service · Statement Business Segments
Source dimensions
srt:ProductOrServiceAxis=amrx:EphinephrineAutoInjectorMember;us-gaap:StatementBusinessSegmentsAxis=amrx:AffordableMedicinesSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-04-01 – 2026-06-30 | 62214000 | USD | 20260806 | Open filing evidence |
| 2026-01-01 – 2026-06-30 | 104126000 | USD | 20260806 | Open filing evidence |
| 2026-01-01 – 2026-03-31 | 41912000 | USD | 20260507 | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 66594000 | USD | 20260806 | Open filing evidence |
| 2025-01-01 – 2025-06-30 | 114754000 | USD | 20260806 | Open filing evidence |
| 2025-01-01 – 2025-03-31 | 48160000 | USD | 20260507 | Open filing evidence |
Gastroenterology · US · Generics Segment
Product Or Service · Statement Geographical · Statement Business Segments
Source dimensions
srt:ProductOrServiceAxis=amrx:GastroenterologyMember;srt:StatementGeographicalAxis=country:US;us-gaap:StatementBusinessSegmentsAxis=amrx:GenericsSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2024-01-01 – 2024-03-31 | 18197000 | USD | 20240508 | Open filing evidence |
Government Label · US · Av KARE Segment
Product Or Service · Statement Geographical · Statement Business Segments
Source dimensions
srt:ProductOrServiceAxis=amrx:GovernmentLabelMember;srt:StatementGeographicalAxis=country:US;us-gaap:StatementBusinessSegmentsAxis=amrx:AvKARESegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2025-01-01 – 2025-12-31 | 270105000 | USD | 20260227 | Open filing evidence |
| 2025-07-01 – 2025-09-30 | 87755000 | USD | 20251106 | Open filing evidence |
| 2025-01-01 – 2025-09-30 | 183313000 | USD | 20251106 | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 45418000 | USD | 20250807 | Open filing evidence |
| 2025-01-01 – 2025-06-30 | 95558000 | USD | 20250807 | Open filing evidence |
| 2024-01-01 – 2024-12-31 | 159957000 | USD | 20260227 | Open filing evidence |
| 2024-07-01 – 2024-09-30 | 41936000 | USD | 20251106 | Open filing evidence |
| 2024-01-01 – 2024-09-30 | 113098000 | USD | 20251106 | Open filing evidence |
| 2024-04-01 – 2024-06-30 | 36210000 | USD | 20250807 | Open filing evidence |
| 2024-01-01 – 2024-06-30 | 71162000 | USD | 20250807 | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 121829000 | USD | 20260227 | Open filing evidence |
Government Label · Av KARE Segment
Product Or Service · Statement Business Segments
Source dimensions
srt:ProductOrServiceAxis=amrx:GovernmentLabelMember;us-gaap:StatementBusinessSegmentsAxis=amrx:AvKARESegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-04-01 – 2026-06-30 | 50207000 | USD | 20260806 | Open filing evidence |
| 2026-01-01 – 2026-06-30 | 110156000 | USD | 20260806 | Open filing evidence |
| 2026-01-01 – 2026-03-31 | 59949000 | USD | 20260507 | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 45418000 | USD | 20260806 | Open filing evidence |
| 2025-01-01 – 2025-06-30 | 95558000 | USD | 20260806 | Open filing evidence |
| 2025-01-01 – 2025-03-31 | 50140000 | USD | 20260507 | Open filing evidence |
Government Label · Av KARE Segment · US
Product Or Service · Statement Business Segments · Statement Geographical
Source dimensions
srt:ProductOrServiceAxis=amrx:GovernmentLabelMember;us-gaap:StatementBusinessSegmentsAxis=amrx:AvKARESegmentMember;srt:StatementGeographicalAxis=country:US| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2023-07-01 – 2023-09-30 | 32764000 | USD | 20231109 | Open filing evidence |
| 2023-01-01 – 2023-09-30 | 87150000 | USD | 20231109 | Open filing evidence |
Hormonal Allergy · US · Generics Segment
Product Or Service · Statement Geographical · Statement Business Segments
Source dimensions
srt:ProductOrServiceAxis=amrx:HormonalAllergyMember;srt:StatementGeographicalAxis=country:US;us-gaap:StatementBusinessSegmentsAxis=amrx:GenericsSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2024-01-01 – 2024-03-31 | 107714000 | USD | 20240508 | Open filing evidence |
Hormonal Allergy · US · Specialty Segment
Product Or Service · Statement Geographical · Statement Business Segments
Source dimensions
srt:ProductOrServiceAxis=amrx:HormonalAllergyMember;srt:StatementGeographicalAxis=country:US;us-gaap:StatementBusinessSegmentsAxis=amrx:SpecialtySegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2025-01-01 – 2025-12-31 | 154927000 | USD | 20260227 | Open filing evidence |
| 2025-07-01 – 2025-09-30 | 37685000 | USD | 20251106 | Open filing evidence |
| 2025-01-01 – 2025-09-30 | 107302000 | USD | 20251106 | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 35418000 | USD | 20250807 | Open filing evidence |
| 2025-01-01 – 2025-06-30 | 69617000 | USD | 20250807 | Open filing evidence |
| 2024-01-01 – 2024-12-31 | 130426000 | USD | 20260227 | Open filing evidence |
| 2024-07-01 – 2024-09-30 | 32283000 | USD | 20251106 | Open filing evidence |
| 2024-01-01 – 2024-09-30 | 93433000 | USD | 20251106 | Open filing evidence |
| 2024-04-01 – 2024-06-30 | 31775000 | USD | 20250807 | Open filing evidence |
| 2024-01-01 – 2024-06-30 | 61150000 | USD | 20250807 | Open filing evidence |
| 2024-01-01 – 2024-03-31 | 29375000 | USD | 20240508 | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 110486000 | USD | 20260227 | Open filing evidence |
Hormonal Allergy · Specialty Segment
Product Or Service · Statement Business Segments
Source dimensions
srt:ProductOrServiceAxis=amrx:HormonalAllergyMember;us-gaap:StatementBusinessSegmentsAxis=amrx:SpecialtySegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-04-01 – 2026-06-30 | 42099000 | USD | 20260806 | Open filing evidence |
| 2026-01-01 – 2026-06-30 | 78031000 | USD | 20260806 | Open filing evidence |
| 2026-01-01 – 2026-03-31 | 35932000 | USD | 20260507 | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 35418000 | USD | 20260806 | Open filing evidence |
| 2025-01-01 – 2025-06-30 | 69617000 | USD | 20260806 | Open filing evidence |
| 2025-01-01 – 2025-03-31 | 34199000 | USD | 20260507 | Open filing evidence |
Injectable · US · Affordable Medicines Segment
Product Or Service · Statement Geographical · Statement Business Segments
Source dimensions
srt:ProductOrServiceAxis=amrx:InjectableMember;srt:StatementGeographicalAxis=country:US;us-gaap:StatementBusinessSegmentsAxis=amrx:AffordableMedicinesSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2025-01-01 – 2025-12-31 | 161239000 | USD | 20260227 | Open filing evidence |
| 2025-07-01 – 2025-09-30 | 54368000 | USD | 20251106 | Open filing evidence |
| 2025-01-01 – 2025-09-30 | 123802000 | USD | 20251106 | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 34646000 | USD | 20250807 | Open filing evidence |
| 2025-01-01 – 2025-06-30 | 69434000 | USD | 20250807 | Open filing evidence |
| 2024-01-01 – 2024-12-31 | 165430000 | USD | 20260227 | Open filing evidence |
| 2024-07-01 – 2024-09-30 | 43169000 | USD | 20251106 | Open filing evidence |
| 2024-01-01 – 2024-09-30 | 117472000 | USD | 20251106 | Open filing evidence |
| 2024-04-01 – 2024-06-30 | 39081000 | USD | 20250807 | Open filing evidence |
| 2024-01-01 – 2024-06-30 | 74303000 | USD | 20250807 | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 141854000 | USD | 20260227 | Open filing evidence |
Injectable · Affordable Medicines Segment
Product Or Service · Statement Business Segments
Source dimensions
srt:ProductOrServiceAxis=amrx:InjectableMember;us-gaap:StatementBusinessSegmentsAxis=amrx:AffordableMedicinesSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-04-01 – 2026-06-30 | 56783000 | USD | 20260806 | Open filing evidence |
| 2026-01-01 – 2026-06-30 | 106721000 | USD | 20260806 | Open filing evidence |
| 2026-01-01 – 2026-03-31 | 49938000 | USD | 20260507 | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 34646000 | USD | 20260806 | Open filing evidence |
| 2025-01-01 – 2025-06-30 | 69434000 | USD | 20260806 | Open filing evidence |
| 2025-01-01 – 2025-03-31 | 34788000 | USD | 20260507 | Open filing evidence |
Institutional · US · Av KARE Segment
Product Or Service · Statement Geographical · Statement Business Segments
Source dimensions
srt:ProductOrServiceAxis=amrx:InstitutionalMember;srt:StatementGeographicalAxis=country:US;us-gaap:StatementBusinessSegmentsAxis=amrx:AvKARESegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2025-01-01 – 2025-12-31 | 35376000 | USD | 20260227 | Open filing evidence |
| 2025-07-01 – 2025-09-30 | 5853000 | USD | 20251106 | Open filing evidence |
| 2025-01-01 – 2025-09-30 | 26994000 | USD | 20251106 | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 10132000 | USD | 20250807 | Open filing evidence |
| 2025-01-01 – 2025-06-30 | 21141000 | USD | 20250807 | Open filing evidence |
| 2024-01-01 – 2024-12-31 | 42750000 | USD | 20260227 | Open filing evidence |
| 2024-07-01 – 2024-09-30 | 9394000 | USD | 20251106 | Open filing evidence |
| 2024-01-01 – 2024-09-30 | 32020000 | USD | 20251106 | Open filing evidence |
| 2024-04-01 – 2024-06-30 | 11768000 | USD | 20250807 | Open filing evidence |
| 2024-01-01 – 2024-06-30 | 22626000 | USD | 20250807 | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 38016000 | USD | 20260227 | Open filing evidence |
Institutional · Av KARE Segment
Product Or Service · Statement Business Segments
Source dimensions
srt:ProductOrServiceAxis=amrx:InstitutionalMember;us-gaap:StatementBusinessSegmentsAxis=amrx:AvKARESegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-04-01 – 2026-06-30 | 12112000 | USD | 20260806 | Open filing evidence |
| 2026-01-01 – 2026-06-30 | 21931000 | USD | 20260806 | Open filing evidence |
| 2026-01-01 – 2026-03-31 | 9819000 | USD | 20260507 | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 10132000 | USD | 20260806 | Open filing evidence |
| 2025-01-01 – 2025-06-30 | 21141000 | USD | 20260806 | Open filing evidence |
| 2025-01-01 – 2025-03-31 | 11009000 | USD | 20260507 | Open filing evidence |
Institutional · Av KARE Segment · US
Product Or Service · Statement Business Segments · Statement Geographical
Source dimensions
srt:ProductOrServiceAxis=amrx:InstitutionalMember;us-gaap:StatementBusinessSegmentsAxis=amrx:AvKARESegmentMember;srt:StatementGeographicalAxis=country:US| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2023-07-01 – 2023-09-30 | 10551000 | USD | 20231109 | Open filing evidence |
| 2023-01-01 – 2023-09-30 | 28395000 | USD | 20231109 | Open filing evidence |
International · US · Affordable Medicines Segment
Product Or Service · Statement Geographical · Statement Business Segments
Source dimensions
srt:ProductOrServiceAxis=amrx:InternationalMember;srt:StatementGeographicalAxis=country:US;us-gaap:StatementBusinessSegmentsAxis=amrx:AffordableMedicinesSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2025-01-01 – 2025-12-31 | 12125000 | USD | 20260227 | Open filing evidence |
| 2025-07-01 – 2025-09-30 | 6288000 | USD | 20251106 | Open filing evidence |
| 2025-01-01 – 2025-09-30 | 9423000 | USD | 20251106 | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 1901000 | USD | 20250807 | Open filing evidence |
| 2025-01-01 – 2025-06-30 | 3135000 | USD | 20250807 | Open filing evidence |
| 2024-01-01 – 2024-12-31 | 8952000 | USD | 20260227 | Open filing evidence |
| 2024-07-01 – 2024-09-30 | 4507000 | USD | 20251106 | Open filing evidence |
| 2024-01-01 – 2024-09-30 | 7658000 | USD | 20251106 | Open filing evidence |
| 2024-04-01 – 2024-06-30 | 1430000 | USD | 20250807 | Open filing evidence |
| 2024-01-01 – 2024-06-30 | 3151000 | USD | 20250807 | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 2165000 | USD | 20260227 | Open filing evidence |
International · Affordable Medicines Segment
Product Or Service · Statement Business Segments
Source dimensions
srt:ProductOrServiceAxis=amrx:InternationalMember;us-gaap:StatementBusinessSegmentsAxis=amrx:AffordableMedicinesSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-04-01 – 2026-06-30 | 7613000 | USD | 20260806 | Open filing evidence |
| 2026-01-01 – 2026-06-30 | 12932000 | USD | 20260806 | Open filing evidence |
| 2026-01-01 – 2026-03-31 | 5319000 | USD | 20260507 | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 1901000 | USD | 20260806 | Open filing evidence |
| 2025-01-01 – 2025-06-30 | 3135000 | USD | 20260806 | Open filing evidence |
| 2025-01-01 – 2025-03-31 | 1234000 | USD | 20260507 | Open filing evidence |
License Agreement · US · Specialty Segment
Product Or Service · Statement Geographical · Statement Business Segments
Source dimensions
srt:ProductOrServiceAxis=amrx:LicenseAgreementMember;srt:StatementGeographicalAxis=country:US;us-gaap:StatementBusinessSegmentsAxis=amrx:SpecialtySegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2025-01-01 – 2025-12-31 | 500000 | USD | 20260227 | Open filing evidence |
| 2025-07-01 – 2025-09-30 | 0 | USD | 20251106 | Open filing evidence |
| 2025-01-01 – 2025-09-30 | 500000 | USD | 20251106 | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 500000 | USD | 20250807 | Open filing evidence |
| 2025-01-01 – 2025-06-30 | 500000 | USD | 20250807 | Open filing evidence |
| 2024-01-01 – 2024-12-31 | 6527000 | USD | 20260227 | Open filing evidence |
| 2024-07-01 – 2024-09-30 | 2048000 | USD | 20251106 | Open filing evidence |
| 2024-01-01 – 2024-09-30 | 6527000 | USD | 20251106 | Open filing evidence |
| 2024-04-01 – 2024-06-30 | 0 | USD | 20250807 | Open filing evidence |
| 2024-01-01 – 2024-06-30 | 4479000 | USD | 20250807 | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 0 | USD | 20260227 | Open filing evidence |
License Agreement · Specialty Segment
Product Or Service · Statement Business Segments
Source dimensions
srt:ProductOrServiceAxis=amrx:LicenseAgreementMember;us-gaap:StatementBusinessSegmentsAxis=amrx:SpecialtySegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-04-01 – 2026-06-30 | 0 | USD | 20260806 | Open filing evidence |
| 2026-01-01 – 2026-06-30 | 0 | USD | 20260806 | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 500000 | USD | 20260806 | Open filing evidence |
| 2025-01-01 – 2025-06-30 | 500000 | USD | 20260806 | Open filing evidence |
Metabolic Disease Endocrine · US · Generics Segment
Product Or Service · Statement Geographical · Statement Business Segments
Source dimensions
srt:ProductOrServiceAxis=amrx:MetabolicDiseaseEndocrineMember;srt:StatementGeographicalAxis=country:US;us-gaap:StatementBusinessSegmentsAxis=amrx:GenericsSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2024-01-01 – 2024-03-31 | 11185000 | USD | 20240508 | Open filing evidence |
Oncology · US · Generics Segment
Product Or Service · Statement Geographical · Statement Business Segments
Source dimensions
srt:ProductOrServiceAxis=amrx:OncologyMember;srt:StatementGeographicalAxis=country:US;us-gaap:StatementBusinessSegmentsAxis=amrx:GenericsSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2024-01-01 – 2024-03-31 | 38533000 | USD | 20240508 | Open filing evidence |
Oncology · Generics Segment · US
Product Or Service · Statement Business Segments · Statement Geographical
Source dimensions
srt:ProductOrServiceAxis=amrx:OncologyMember;us-gaap:StatementBusinessSegmentsAxis=amrx:GenericsSegmentMember;srt:StatementGeographicalAxis=country:US| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2023-07-01 – 2023-09-30 | 37722000 | USD | 20231109 | Open filing evidence |
| 2023-01-01 – 2023-09-30 | 76846000 | USD | 20231109 | Open filing evidence |
Oral Liquid · US · Affordable Medicines Segment
Product Or Service · Statement Geographical · Statement Business Segments
Source dimensions
srt:ProductOrServiceAxis=amrx:OralLiquidMember;srt:StatementGeographicalAxis=country:US;us-gaap:StatementBusinessSegmentsAxis=amrx:AffordableMedicinesSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2025-01-01 – 2025-12-31 | 72821000 | USD | 20260227 | Open filing evidence |
| 2025-07-01 – 2025-09-30 | 16415000 | USD | 20251106 | Open filing evidence |
| 2025-01-01 – 2025-09-30 | 57842000 | USD | 20251106 | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 17879000 | USD | 20250807 | Open filing evidence |
| 2025-01-01 – 2025-06-30 | 41427000 | USD | 20250807 | Open filing evidence |
| 2024-01-01 – 2024-12-31 | 103421000 | USD | 20260227 | Open filing evidence |
| 2024-07-01 – 2024-09-30 | 22543000 | USD | 20251106 | Open filing evidence |
| 2024-01-01 – 2024-09-30 | 78568000 | USD | 20251106 | Open filing evidence |
| 2024-04-01 – 2024-06-30 | 24096000 | USD | 20250807 | Open filing evidence |
| 2024-01-01 – 2024-06-30 | 56025000 | USD | 20250807 | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 111045000 | USD | 20260227 | Open filing evidence |
Oral Liquid · Affordable Medicines Segment
Product Or Service · Statement Business Segments
Source dimensions
srt:ProductOrServiceAxis=amrx:OralLiquidMember;us-gaap:StatementBusinessSegmentsAxis=amrx:AffordableMedicinesSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-04-01 – 2026-06-30 | 10371000 | USD | 20260806 | Open filing evidence |
| 2026-01-01 – 2026-06-30 | 22463000 | USD | 20260806 | Open filing evidence |
| 2026-01-01 – 2026-03-31 | 12092000 | USD | 20260507 | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 17879000 | USD | 20260806 | Open filing evidence |
| 2025-01-01 – 2025-06-30 | 41427000 | USD | 20260806 | Open filing evidence |
| 2025-01-01 – 2025-03-31 | 23548000 | USD | 20260507 | Open filing evidence |
Oral Solid · US · Affordable Medicines Segment
Product Or Service · Statement Geographical · Statement Business Segments
Source dimensions
srt:ProductOrServiceAxis=amrx:OralSolidMember;srt:StatementGeographicalAxis=country:US;us-gaap:StatementBusinessSegmentsAxis=amrx:AffordableMedicinesSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2025-01-01 – 2025-12-31 | 726383000 | USD | 20260227 | Open filing evidence |
| 2025-07-01 – 2025-09-30 | 180460000 | USD | 20251106 | Open filing evidence |
| 2025-01-01 – 2025-09-30 | 537675000 | USD | 20251106 | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 178262000 | USD | 20250807 | Open filing evidence |
| 2025-01-01 – 2025-06-30 | 357215000 | USD | 20250807 | Open filing evidence |
| 2024-01-01 – 2024-12-31 | 689436000 | USD | 20260227 | Open filing evidence |
| 2024-07-01 – 2024-09-30 | 161215000 | USD | 20251106 | Open filing evidence |
| 2024-01-01 – 2024-09-30 | 506484000 | USD | 20251106 | Open filing evidence |
| 2024-04-01 – 2024-06-30 | 175956000 | USD | 20250807 | Open filing evidence |
| 2024-01-01 – 2024-06-30 | 345269000 | USD | 20250807 | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 649998000 | USD | 20260227 | Open filing evidence |
Oral Solid · Affordable Medicines Segment
Product Or Service · Statement Business Segments
Source dimensions
srt:ProductOrServiceAxis=amrx:OralSolidMember;us-gaap:StatementBusinessSegmentsAxis=amrx:AffordableMedicinesSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-04-01 – 2026-06-30 | 175172000 | USD | 20260806 | Open filing evidence |
| 2026-01-01 – 2026-06-30 | 346272000 | USD | 20260806 | Open filing evidence |
| 2026-01-01 – 2026-03-31 | 171100000 | USD | 20260507 | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 178262000 | USD | 20260806 | Open filing evidence |
| 2025-01-01 – 2025-06-30 | 357215000 | USD | 20260806 | Open filing evidence |
| 2025-01-01 – 2025-03-31 | 178953000 | USD | 20260507 | Open filing evidence |
Other Dosage Forms · US · Affordable Medicines Segment
Product Or Service · Statement Geographical · Statement Business Segments
Source dimensions
srt:ProductOrServiceAxis=amrx:OtherDosageFormsMember;srt:StatementGeographicalAxis=country:US;us-gaap:StatementBusinessSegmentsAxis=amrx:AffordableMedicinesSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2025-01-01 – 2025-12-31 | 252421000 | USD | 20260227 | Open filing evidence |
| 2025-07-01 – 2025-09-30 | 59662000 | USD | 20251106 | Open filing evidence |
| 2025-01-01 – 2025-09-30 | 184269000 | USD | 20251106 | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 68185000 | USD | 20250807 | Open filing evidence |
| 2025-01-01 – 2025-06-30 | 124607000 | USD | 20250807 | Open filing evidence |
| 2024-01-01 – 2024-12-31 | 202188000 | USD | 20260227 | Open filing evidence |
| 2024-07-01 – 2024-09-30 | 50652000 | USD | 20251106 | Open filing evidence |
| 2024-01-01 – 2024-09-30 | 143213000 | USD | 20251106 | Open filing evidence |
| 2024-04-01 – 2024-06-30 | 49287000 | USD | 20250807 | Open filing evidence |
| 2024-01-01 – 2024-06-30 | 92561000 | USD | 20250807 | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 180479000 | USD | 20260227 | Open filing evidence |
Other Dosage Forms · Affordable Medicines Segment
Product Or Service · Statement Business Segments
Source dimensions
srt:ProductOrServiceAxis=amrx:OtherDosageFormsMember;us-gaap:StatementBusinessSegmentsAxis=amrx:AffordableMedicinesSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-04-01 – 2026-06-30 | 81594000 | USD | 20260806 | Open filing evidence |
| 2026-01-01 – 2026-06-30 | 128206000 | USD | 20260806 | Open filing evidence |
| 2026-01-01 – 2026-03-31 | 46612000 | USD | 20260507 | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 68185000 | USD | 20260806 | Open filing evidence |
| 2025-01-01 – 2025-06-30 | 124607000 | USD | 20260806 | Open filing evidence |
| 2025-01-01 – 2025-03-31 | 56422000 | USD | 20260507 | Open filing evidence |
Other Therapeutic Classes · US · Specialty Segment
Product Or Service · Statement Geographical · Statement Business Segments
Source dimensions
srt:ProductOrServiceAxis=amrx:OtherTherapeuticClassesMember;srt:StatementGeographicalAxis=country:US;us-gaap:StatementBusinessSegmentsAxis=amrx:SpecialtySegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2025-01-01 – 2025-12-31 | 39664000 | USD | 20260227 | Open filing evidence |
| 2025-07-01 – 2025-09-30 | 9924000 | USD | 20251106 | Open filing evidence |
| 2025-01-01 – 2025-09-30 | 25112000 | USD | 20251106 | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 8700000 | USD | 20250807 | Open filing evidence |
| 2025-01-01 – 2025-06-30 | 15188000 | USD | 20250807 | Open filing evidence |
| 2024-01-01 – 2024-12-31 | 28622000 | USD | 20260227 | Open filing evidence |
| 2024-07-01 – 2024-09-30 | 7906000 | USD | 20251106 | Open filing evidence |
| 2024-01-01 – 2024-09-30 | 21370000 | USD | 20251106 | Open filing evidence |
| 2024-04-01 – 2024-06-30 | 8360000 | USD | 20250807 | Open filing evidence |
| 2024-01-01 – 2024-06-30 | 13464000 | USD | 20250807 | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 29990000 | USD | 20260227 | Open filing evidence |
Other Therapeutic Classes · Generics Segment · US
Product Or Service · Statement Business Segments · Statement Geographical
Source dimensions
srt:ProductOrServiceAxis=amrx:OtherTherapeuticClassesMember;us-gaap:StatementBusinessSegmentsAxis=amrx:GenericsSegmentMember;srt:StatementGeographicalAxis=country:US| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2023-07-01 – 2023-09-30 | 27270000 | USD | 20231109 | Open filing evidence |
| 2023-01-01 – 2023-09-30 | 80974000 | USD | 20231109 | Open filing evidence |
Other Therapeutic Classes · Specialty Segment
Product Or Service · Statement Business Segments
Source dimensions
srt:ProductOrServiceAxis=amrx:OtherTherapeuticClassesMember;us-gaap:StatementBusinessSegmentsAxis=amrx:SpecialtySegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-04-01 – 2026-06-30 | 11852000 | USD | 20260806 | Open filing evidence |
| 2026-01-01 – 2026-06-30 | 25802000 | USD | 20260806 | Open filing evidence |
| 2026-01-01 – 2026-03-31 | 13950000 | USD | 20260507 | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 8700000 | USD | 20260806 | Open filing evidence |
| 2025-01-01 – 2025-06-30 | 15188000 | USD | 20260806 | Open filing evidence |
| 2025-01-01 – 2025-03-31 | 6488000 | USD | 20260507 | Open filing evidence |
Other Therapeutic Classes · Specialty Segment · US
Product Or Service · Statement Business Segments · Statement Geographical
Source dimensions
srt:ProductOrServiceAxis=amrx:OtherTherapeuticClassesMember;us-gaap:StatementBusinessSegmentsAxis=amrx:SpecialtySegmentMember;srt:StatementGeographicalAxis=country:US| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2023-01-01 – 2023-12-31 | 29990000 | USD | 20240314 | Open filing evidence |
| 2023-07-01 – 2023-09-30 | 7668000 | USD | 20231109 | Open filing evidence |
| 2023-01-01 – 2023-09-30 | 22864000 | USD | 20231109 | Open filing evidence |
Subtotal Dosage Forms · US · Affordable Medicines Segment
Product Or Service · Statement Geographical · Statement Business Segments
Source dimensions
srt:ProductOrServiceAxis=amrx:SubtotalDosageFormsMember;srt:StatementGeographicalAxis=country:US;us-gaap:StatementBusinessSegmentsAxis=amrx:AffordableMedicinesSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2025-01-01 – 2025-12-31 | 1733399000 | USD | 20260227 | Open filing evidence |
| 2025-07-01 – 2025-09-30 | 454453000 | USD | 20251106 | Open filing evidence |
| 2025-01-01 – 2025-09-30 | 1299451000 | USD | 20251106 | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 431524000 | USD | 20250807 | Open filing evidence |
| 2025-01-01 – 2025-06-30 | 844998000 | USD | 20250807 | Open filing evidence |
| 2024-01-01 – 2024-12-31 | 1676311000 | USD | 20260227 | Open filing evidence |
| 2024-07-01 – 2024-09-30 | 422838000 | USD | 20251106 | Open filing evidence |
| 2024-01-01 – 2024-09-30 | 1238309000 | USD | 20251106 | Open filing evidence |
| 2024-04-01 – 2024-06-30 | 425898000 | USD | 20250807 | Open filing evidence |
| 2024-01-01 – 2024-06-30 | 815471000 | USD | 20250807 | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 1469236000 | USD | 20260227 | Open filing evidence |
Subtotal Dosage Forms · Affordable Medicines Segment
Product Or Service · Statement Business Segments
Source dimensions
srt:ProductOrServiceAxis=amrx:SubtotalDosageFormsMember;us-gaap:StatementBusinessSegmentsAxis=amrx:AffordableMedicinesSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-04-01 – 2026-06-30 | 482300000 | USD | 20260806 | Open filing evidence |
| 2026-01-01 – 2026-06-30 | 900218000 | USD | 20260806 | Open filing evidence |
| 2026-01-01 – 2026-03-31 | 417918000 | USD | 20260507 | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 431524000 | USD | 20260806 | Open filing evidence |
| 2025-01-01 – 2025-06-30 | 844998000 | USD | 20260806 | Open filing evidence |
| 2025-01-01 – 2025-03-31 | 413474000 | USD | 20260507 | Open filing evidence |
Subtotal Therapeutic Classes · US · Specialty Segment
Product Or Service · Statement Geographical · Statement Business Segments
Source dimensions
srt:ProductOrServiceAxis=amrx:SubtotalTherapeuticClassesMember;srt:StatementGeographicalAxis=country:US;us-gaap:StatementBusinessSegmentsAxis=amrx:SpecialtySegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2025-01-01 – 2025-12-31 | 528008000 | USD | 20260227 | Open filing evidence |
| 2025-07-01 – 2025-09-30 | 125240000 | USD | 20251106 | Open filing evidence |
| 2025-01-01 – 2025-09-30 | 361080000 | USD | 20251106 | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 127543000 | USD | 20250807 | Open filing evidence |
| 2025-01-01 – 2025-06-30 | 235840000 | USD | 20250807 | Open filing evidence |
| 2024-01-01 – 2024-12-31 | 439222000 | USD | 20260227 | Open filing evidence |
| 2024-07-01 – 2024-09-30 | 113590000 | USD | 20251106 | Open filing evidence |
| 2024-01-01 – 2024-09-30 | 318386000 | USD | 20251106 | Open filing evidence |
| 2024-04-01 – 2024-06-30 | 104041000 | USD | 20250807 | Open filing evidence |
| 2024-01-01 – 2024-06-30 | 204796000 | USD | 20250807 | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 390457000 | USD | 20260227 | Open filing evidence |
Subtotal Therapeutic Classes · Specialty Segment
Product Or Service · Statement Business Segments
Source dimensions
srt:ProductOrServiceAxis=amrx:SubtotalTherapeuticClassesMember;us-gaap:StatementBusinessSegmentsAxis=amrx:SpecialtySegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-04-01 – 2026-06-30 | 149295000 | USD | 20260806 | Open filing evidence |
| 2026-01-01 – 2026-06-30 | 282560000 | USD | 20260806 | Open filing evidence |
| 2026-01-01 – 2026-03-31 | 133265000 | USD | 20260507 | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 127543000 | USD | 20260806 | Open filing evidence |
| 2025-01-01 – 2025-06-30 | 235840000 | USD | 20260806 | Open filing evidence |
| 2025-01-01 – 2025-03-31 | 108297000 | USD | 20260507 | Open filing evidence |
Transdermal · US · Affordable Medicines Segment
Product Or Service · Statement Geographical · Statement Business Segments
Source dimensions
srt:ProductOrServiceAxis=amrx:TransdermalMember;srt:StatementGeographicalAxis=country:US;us-gaap:StatementBusinessSegmentsAxis=amrx:AffordableMedicinesSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2025-01-01 – 2025-12-31 | 187511000 | USD | 20260227 | Open filing evidence |
| 2025-07-01 – 2025-09-30 | 47599000 | USD | 20251106 | Open filing evidence |
| 2025-01-01 – 2025-09-30 | 131372000 | USD | 20251106 | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 40710000 | USD | 20250807 | Open filing evidence |
| 2025-01-01 – 2025-06-30 | 83773000 | USD | 20250807 | Open filing evidence |
| 2024-01-01 – 2024-12-31 | 180917000 | USD | 20260227 | Open filing evidence |
| 2024-07-01 – 2024-09-30 | 43891000 | USD | 20251106 | Open filing evidence |
| 2024-01-01 – 2024-09-30 | 134113000 | USD | 20251106 | Open filing evidence |
| 2024-04-01 – 2024-06-30 | 49697000 | USD | 20250807 | Open filing evidence |
| 2024-01-01 – 2024-06-30 | 90222000 | USD | 20250807 | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 159084000 | USD | 20260227 | Open filing evidence |
Transdermal · Affordable Medicines Segment
Product Or Service · Statement Business Segments
Source dimensions
srt:ProductOrServiceAxis=amrx:TransdermalMember;us-gaap:StatementBusinessSegmentsAxis=amrx:AffordableMedicinesSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-04-01 – 2026-06-30 | 67038000 | USD | 20260806 | Open filing evidence |
| 2026-01-01 – 2026-06-30 | 141001000 | USD | 20260806 | Open filing evidence |
| 2026-01-01 – 2026-03-31 | 73963000 | USD | 20260507 | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 40710000 | USD | 20260806 | Open filing evidence |
| 2025-01-01 – 2025-06-30 | 83773000 | USD | 20260806 | Open filing evidence |
| 2025-01-01 – 2025-03-31 | 43063000 | USD | 20260507 | Open filing evidence |
Distribution Service · US · Av KARE Segment
Product Or Service · Statement Geographical · Statement Business Segments
Source dimensions
srt:ProductOrServiceAxis=us-gaap:DistributionServiceMember;srt:StatementGeographicalAxis=country:US;us-gaap:StatementBusinessSegmentsAxis=amrx:AvKARESegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2025-01-01 – 2025-12-31 | 408456000 | USD | 20260227 | Open filing evidence |
| 2025-07-01 – 2025-09-30 | 96216000 | USD | 20251106 | Open filing evidence |
| 2025-01-01 – 2025-09-30 | 300774000 | USD | 20251106 | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 99663000 | USD | 20250807 | Open filing evidence |
| 2025-01-01 – 2025-06-30 | 204558000 | USD | 20250807 | Open filing evidence |
| 2024-01-01 – 2024-12-31 | 433981000 | USD | 20260227 | Open filing evidence |
| 2024-07-01 – 2024-09-30 | 101605000 | USD | 20251106 | Open filing evidence |
| 2024-01-01 – 2024-09-30 | 327453000 | USD | 20251106 | Open filing evidence |
| 2024-04-01 – 2024-06-30 | 116135000 | USD | 20250807 | Open filing evidence |
| 2024-01-01 – 2024-06-30 | 225848000 | USD | 20250807 | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 347406000 | USD | 20260227 | Open filing evidence |
Distribution Service · Av KARE Segment
Product Or Service · Statement Business Segments
Source dimensions
srt:ProductOrServiceAxis=us-gaap:DistributionServiceMember;us-gaap:StatementBusinessSegmentsAxis=amrx:AvKARESegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-04-01 – 2026-06-30 | 86930000 | USD | 20260806 | Open filing evidence |
| 2026-01-01 – 2026-06-30 | 176079000 | USD | 20260806 | Open filing evidence |
| 2026-01-01 – 2026-03-31 | 89149000 | USD | 20260507 | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 99663000 | USD | 20260806 | Open filing evidence |
| 2025-01-01 – 2025-06-30 | 204558000 | USD | 20260806 | Open filing evidence |
| 2025-01-01 – 2025-03-31 | 104895000 | USD | 20260507 | Open filing evidence |
Product And Service Other · US · Av KARE Segment
Product Or Service · Statement Geographical · Statement Business Segments
Source dimensions
srt:ProductOrServiceAxis=us-gaap:ProductAndServiceOtherMember;srt:StatementGeographicalAxis=country:US;us-gaap:StatementBusinessSegmentsAxis=amrx:AvKARESegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2025-01-01 – 2025-12-31 | 30791000 | USD | 20260227 | Open filing evidence |
| 2025-07-01 – 2025-09-30 | 8708000 | USD | 20251106 | Open filing evidence |
| 2025-01-01 – 2025-09-30 | 22906000 | USD | 20251106 | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 7827000 | USD | 20250807 | Open filing evidence |
| 2025-01-01 – 2025-06-30 | 14198000 | USD | 20250807 | Open filing evidence |
| 2024-01-01 – 2024-12-31 | 26257000 | USD | 20260227 | Open filing evidence |
| 2024-07-01 – 2024-09-30 | 6550000 | USD | 20251106 | Open filing evidence |
| 2024-01-01 – 2024-09-30 | 19988000 | USD | 20251106 | Open filing evidence |
| 2024-04-01 – 2024-06-30 | 6298000 | USD | 20250807 | Open filing evidence |
| 2024-01-01 – 2024-06-30 | 13438000 | USD | 20250807 | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 24498000 | USD | 20260227 | Open filing evidence |
Product And Service Other · Av KARE Segment
Product Or Service · Statement Business Segments
Source dimensions
srt:ProductOrServiceAxis=us-gaap:ProductAndServiceOtherMember;us-gaap:StatementBusinessSegmentsAxis=amrx:AvKARESegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-04-01 – 2026-06-30 | 7740000 | USD | 20260806 | Open filing evidence |
| 2026-01-01 – 2026-06-30 | 14840000 | USD | 20260806 | Open filing evidence |
| 2026-01-01 – 2026-03-31 | 7100000 | USD | 20260507 | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 7827000 | USD | 20260806 | Open filing evidence |
| 2025-01-01 – 2025-06-30 | 14198000 | USD | 20260806 | Open filing evidence |
| 2025-01-01 – 2025-03-31 | 6371000 | USD | 20260507 | Open filing evidence |
US · Anti Infective · Generics Segment
Statement Geographical · Product Or Service · Statement Business Segments
Source dimensions
srt:StatementGeographicalAxis=country:US;srt:ProductOrServiceAxis=amrx:AntiInfectiveMember;us-gaap:StatementBusinessSegmentsAxis=amrx:GenericsSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2024-07-01 – 2024-09-30 | 5454000 | USD | 20241112 | Open filing evidence |
| 2024-01-01 – 2024-09-30 | 17966000 | USD | 20241112 | Open filing evidence |
| 2024-04-01 – 2024-06-30 | 6402000 | USD | 20240809 | Open filing evidence |
| 2024-01-01 – 2024-06-30 | 12512000 | USD | 20240809 | Open filing evidence |
| 2023-07-01 – 2023-09-30 | 7382000 | USD | 20241112 | Open filing evidence |
| 2023-01-01 – 2023-09-30 | 18648000 | USD | 20241112 | Open filing evidence |
US · Antiviral · Generics Segment
Statement Geographical · Product Or Service · Statement Business Segments
Source dimensions
srt:StatementGeographicalAxis=country:US;srt:ProductOrServiceAxis=amrx:AntiviralMember;us-gaap:StatementBusinessSegmentsAxis=amrx:GenericsSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2024-07-01 – 2024-09-30 | 4371000 | USD | 20241112 | Open filing evidence |
| 2024-01-01 – 2024-09-30 | 12544000 | USD | 20241112 | Open filing evidence |
| 2024-04-01 – 2024-06-30 | 4307000 | USD | 20240809 | Open filing evidence |
| 2024-01-01 – 2024-06-30 | 8173000 | USD | 20240809 | Open filing evidence |
| 2023-07-01 – 2023-09-30 | 7150000 | USD | 20241112 | Open filing evidence |
| 2023-01-01 – 2023-09-30 | 36221000 | USD | 20241112 | Open filing evidence |
US · Biosimilar · Affordable Medicines Segment
Statement Geographical · Product Or Service · Statement Business Segments
Source dimensions
srt:StatementGeographicalAxis=country:US;srt:ProductOrServiceAxis=amrx:BiosimilarMember;us-gaap:StatementBusinessSegmentsAxis=amrx:AffordableMedicinesSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2025-01-01 – 2025-03-31 | 28540000 | USD | 20250507 | Open filing evidence |
| 2024-01-01 – 2024-12-31 | 125422000 | USD | 20250228 | Open filing evidence |
| 2024-01-01 – 2024-03-31 | 26692000 | USD | 20250507 | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 65923000 | USD | 20250228 | Open filing evidence |
US · Cardiovascular System · Generics Segment
Statement Geographical · Product Or Service · Statement Business Segments
Source dimensions
srt:StatementGeographicalAxis=country:US;srt:ProductOrServiceAxis=amrx:CardiovascularSystemMember;us-gaap:StatementBusinessSegmentsAxis=amrx:GenericsSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2024-07-01 – 2024-09-30 | 36420000 | USD | 20241112 | Open filing evidence |
| 2024-01-01 – 2024-09-30 | 123629000 | USD | 20241112 | Open filing evidence |
| 2024-04-01 – 2024-06-30 | 41331000 | USD | 20240809 | Open filing evidence |
| 2024-01-01 – 2024-06-30 | 87209000 | USD | 20240809 | Open filing evidence |
| 2024-01-01 – 2024-03-31 | 45878000 | USD | 20240508 | Open filing evidence |
| 2023-07-01 – 2023-09-30 | 32459000 | USD | 20241112 | Open filing evidence |
| 2023-01-01 – 2023-09-30 | 98108000 | USD | 20241112 | Open filing evidence |
US · Central Nervous System · Generics Segment
Statement Geographical · Product Or Service · Statement Business Segments
Source dimensions
srt:StatementGeographicalAxis=country:US;srt:ProductOrServiceAxis=amrx:CentralNervousSystemMember;us-gaap:StatementBusinessSegmentsAxis=amrx:GenericsSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2024-07-01 – 2024-09-30 | 108962000 | USD | 20241112 | Open filing evidence |
| 2024-01-01 – 2024-09-30 | 340186000 | USD | 20241112 | Open filing evidence |
| 2024-04-01 – 2024-06-30 | 121768000 | USD | 20240809 | Open filing evidence |
| 2024-01-01 – 2024-06-30 | 231224000 | USD | 20240809 | Open filing evidence |
| 2023-07-01 – 2023-09-30 | 96587000 | USD | 20241112 | Open filing evidence |
| 2023-01-01 – 2023-09-30 | 264773000 | USD | 20241112 | Open filing evidence |
US · Central Nervous System · Specialty Segment
Statement Geographical · Product Or Service · Statement Business Segments
Source dimensions
srt:StatementGeographicalAxis=country:US;srt:ProductOrServiceAxis=amrx:CentralNervousSystemMember;us-gaap:StatementBusinessSegmentsAxis=amrx:SpecialtySegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2025-01-01 – 2025-03-31 | 67610000 | USD | 20250507 | Open filing evidence |
| 2024-01-01 – 2024-12-31 | 280174000 | USD | 20250228 | Open filing evidence |
| 2024-07-01 – 2024-09-30 | 73401000 | USD | 20241112 | Open filing evidence |
| 2024-01-01 – 2024-09-30 | 203583000 | USD | 20241112 | Open filing evidence |
| 2024-04-01 – 2024-06-30 | 63906000 | USD | 20240809 | Open filing evidence |
| 2024-01-01 – 2024-06-30 | 130182000 | USD | 20240809 | Open filing evidence |
| 2024-01-01 – 2024-03-31 | 66276000 | USD | 20250507 | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 249981000 | USD | 20250228 | Open filing evidence |
| 2023-07-01 – 2023-09-30 | 61142000 | USD | 20241112 | Open filing evidence |
| 2023-01-01 – 2023-09-30 | 180844000 | USD | 20241112 | Open filing evidence |
US · Dermatology · Generics Segment
Statement Geographical · Product Or Service · Statement Business Segments
Source dimensions
srt:StatementGeographicalAxis=country:US;srt:ProductOrServiceAxis=amrx:DermatologyMember;us-gaap:StatementBusinessSegmentsAxis=amrx:GenericsSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2024-07-01 – 2024-09-30 | 19280000 | USD | 20241112 | Open filing evidence |
| 2024-01-01 – 2024-09-30 | 58829000 | USD | 20241112 | Open filing evidence |
| 2024-04-01 – 2024-06-30 | 20574000 | USD | 20240809 | Open filing evidence |
| 2024-01-01 – 2024-06-30 | 39549000 | USD | 20240809 | Open filing evidence |
| 2023-07-01 – 2023-09-30 | 17279000 | USD | 20241112 | Open filing evidence |
| 2023-01-01 – 2023-09-30 | 53232000 | USD | 20241112 | Open filing evidence |
US · Ephinephrine Auto Injector · Affordable Medicines Segment
Statement Geographical · Product Or Service · Statement Business Segments
Source dimensions
srt:StatementGeographicalAxis=country:US;srt:ProductOrServiceAxis=amrx:EphinephrineAutoInjectorMember;us-gaap:StatementBusinessSegmentsAxis=amrx:AffordableMedicinesSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2025-01-01 – 2025-03-31 | 48160000 | USD | 20250507 | Open filing evidence |
| 2024-01-01 – 2024-12-31 | 209497000 | USD | 20250228 | Open filing evidence |
| 2024-01-01 – 2024-03-31 | 42618000 | USD | 20250507 | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 160853000 | USD | 20250228 | Open filing evidence |
US · Gastroenterology · Generics Segment
Statement Geographical · Product Or Service · Statement Business Segments
Source dimensions
srt:StatementGeographicalAxis=country:US;srt:ProductOrServiceAxis=amrx:GastroenterologyMember;us-gaap:StatementBusinessSegmentsAxis=amrx:GenericsSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2024-07-01 – 2024-09-30 | 14467000 | USD | 20241112 | Open filing evidence |
| 2024-01-01 – 2024-09-30 | 45391000 | USD | 20241112 | Open filing evidence |
| 2024-04-01 – 2024-06-30 | 12727000 | USD | 20240809 | Open filing evidence |
| 2024-01-01 – 2024-06-30 | 30924000 | USD | 20240809 | Open filing evidence |
| 2023-07-01 – 2023-09-30 | 18858000 | USD | 20241112 | Open filing evidence |
| 2023-01-01 – 2023-09-30 | 53127000 | USD | 20241112 | Open filing evidence |
US · Government Label · Av KARE Segment
Statement Geographical · Product Or Service · Statement Business Segments
Source dimensions
srt:StatementGeographicalAxis=country:US;srt:ProductOrServiceAxis=amrx:GovernmentLabelMember;us-gaap:StatementBusinessSegmentsAxis=amrx:AvKARESegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2025-01-01 – 2025-03-31 | 50140000 | USD | 20250507 | Open filing evidence |
| 2024-01-01 – 2024-12-31 | 159957000 | USD | 20250228 | Open filing evidence |
| 2024-07-01 – 2024-09-30 | 41936000 | USD | 20241112 | Open filing evidence |
| 2024-01-01 – 2024-09-30 | 113098000 | USD | 20241112 | Open filing evidence |
| 2024-04-01 – 2024-06-30 | 36210000 | USD | 20240809 | Open filing evidence |
| 2024-01-01 – 2024-06-30 | 71162000 | USD | 20240809 | Open filing evidence |
| 2024-01-01 – 2024-03-31 | 34952000 | USD | 20250507 | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 121829000 | USD | 20250228 | Open filing evidence |
| 2023-07-01 – 2023-09-30 | 32764000 | USD | 20241112 | Open filing evidence |
| 2023-01-01 – 2023-09-30 | 87150000 | USD | 20241112 | Open filing evidence |
US · Hormonal Allergy · Generics Segment
Statement Geographical · Product Or Service · Statement Business Segments
Source dimensions
srt:StatementGeographicalAxis=country:US;srt:ProductOrServiceAxis=amrx:HormonalAllergyMember;us-gaap:StatementBusinessSegmentsAxis=amrx:GenericsSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2024-07-01 – 2024-09-30 | 132643000 | USD | 20241112 | Open filing evidence |
| 2024-01-01 – 2024-09-30 | 363930000 | USD | 20241112 | Open filing evidence |
| 2024-04-01 – 2024-06-30 | 123573000 | USD | 20240809 | Open filing evidence |
| 2024-01-01 – 2024-06-30 | 231287000 | USD | 20240809 | Open filing evidence |
| 2023-07-01 – 2023-09-30 | 126425000 | USD | 20241112 | Open filing evidence |
| 2023-01-01 – 2023-09-30 | 357711000 | USD | 20241112 | Open filing evidence |
US · Hormonal Allergy · Specialty Segment
Statement Geographical · Product Or Service · Statement Business Segments
Source dimensions
srt:StatementGeographicalAxis=country:US;srt:ProductOrServiceAxis=amrx:HormonalAllergyMember;us-gaap:StatementBusinessSegmentsAxis=amrx:SpecialtySegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2025-01-01 – 2025-03-31 | 34199000 | USD | 20250507 | Open filing evidence |
| 2024-01-01 – 2024-12-31 | 130426000 | USD | 20250228 | Open filing evidence |
| 2024-07-01 – 2024-09-30 | 32283000 | USD | 20241112 | Open filing evidence |
| 2024-01-01 – 2024-09-30 | 93433000 | USD | 20241112 | Open filing evidence |
| 2024-04-01 – 2024-06-30 | 31775000 | USD | 20240809 | Open filing evidence |
| 2024-01-01 – 2024-06-30 | 61150000 | USD | 20240809 | Open filing evidence |
| 2024-01-01 – 2024-03-31 | 29375000 | USD | 20250507 | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 110486000 | USD | 20250228 | Open filing evidence |
| 2023-07-01 – 2023-09-30 | 28494000 | USD | 20241112 | Open filing evidence |
| 2023-01-01 – 2023-09-30 | 82268000 | USD | 20241112 | Open filing evidence |
US · Injectable · Affordable Medicines Segment
Statement Geographical · Product Or Service · Statement Business Segments
Source dimensions
srt:StatementGeographicalAxis=country:US;srt:ProductOrServiceAxis=amrx:InjectableMember;us-gaap:StatementBusinessSegmentsAxis=amrx:AffordableMedicinesSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2025-01-01 – 2025-03-31 | 34788000 | USD | 20250507 | Open filing evidence |
| 2024-01-01 – 2024-12-31 | 165430000 | USD | 20250228 | Open filing evidence |
| 2024-01-01 – 2024-03-31 | 35222000 | USD | 20250507 | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 141854000 | USD | 20250228 | Open filing evidence |
US · Institutional · Av KARE Segment
Statement Geographical · Product Or Service · Statement Business Segments
Source dimensions
srt:StatementGeographicalAxis=country:US;srt:ProductOrServiceAxis=amrx:InstitutionalMember;us-gaap:StatementBusinessSegmentsAxis=amrx:AvKARESegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2025-01-01 – 2025-03-31 | 11009000 | USD | 20250507 | Open filing evidence |
| 2024-01-01 – 2024-12-31 | 42750000 | USD | 20250228 | Open filing evidence |
| 2024-07-01 – 2024-09-30 | 9394000 | USD | 20241112 | Open filing evidence |
| 2024-01-01 – 2024-09-30 | 32020000 | USD | 20241112 | Open filing evidence |
| 2024-04-01 – 2024-06-30 | 11768000 | USD | 20240809 | Open filing evidence |
| 2024-01-01 – 2024-06-30 | 22626000 | USD | 20240809 | Open filing evidence |
| 2024-01-01 – 2024-03-31 | 10858000 | USD | 20250507 | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 38016000 | USD | 20250228 | Open filing evidence |
| 2023-07-01 – 2023-09-30 | 10551000 | USD | 20241112 | Open filing evidence |
| 2023-01-01 – 2023-09-30 | 28395000 | USD | 20241112 | Open filing evidence |
US · International · Affordable Medicines Segment
Statement Geographical · Product Or Service · Statement Business Segments
Source dimensions
srt:StatementGeographicalAxis=country:US;srt:ProductOrServiceAxis=amrx:InternationalMember;us-gaap:StatementBusinessSegmentsAxis=amrx:AffordableMedicinesSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2025-01-01 – 2025-03-31 | 1234000 | USD | 20250507 | Open filing evidence |
| 2024-01-01 – 2024-12-31 | 8952000 | USD | 20250228 | Open filing evidence |
| 2024-01-01 – 2024-03-31 | 1721000 | USD | 20250507 | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 2165000 | USD | 20250228 | Open filing evidence |
US · License Agreement · Affordable Medicines Segment
Statement Geographical · Product Or Service · Statement Business Segments
Source dimensions
srt:StatementGeographicalAxis=country:US;srt:ProductOrServiceAxis=amrx:LicenseAgreementMember;us-gaap:StatementBusinessSegmentsAxis=amrx:AffordableMedicinesSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2024-01-01 – 2024-12-31 | 0 | USD | 20250228 | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 0 | USD | 20250228 | Open filing evidence |
US · License Agreement · Specialty Segment
Statement Geographical · Product Or Service · Statement Business Segments
Source dimensions
srt:StatementGeographicalAxis=country:US;srt:ProductOrServiceAxis=amrx:LicenseAgreementMember;us-gaap:StatementBusinessSegmentsAxis=amrx:SpecialtySegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2025-01-01 – 2025-03-31 | 0 | USD | 20250507 | Open filing evidence |
| 2024-01-01 – 2024-12-31 | 6527000 | USD | 20250228 | Open filing evidence |
| 2024-07-01 – 2024-09-30 | 2048000 | USD | 20241112 | Open filing evidence |
| 2024-01-01 – 2024-09-30 | 6527000 | USD | 20241112 | Open filing evidence |
| 2024-04-01 – 2024-06-30 | 0 | USD | 20240809 | Open filing evidence |
| 2024-01-01 – 2024-06-30 | 4479000 | USD | 20240809 | Open filing evidence |
| 2024-01-01 – 2024-03-31 | 4479000 | USD | 20250507 | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 0 | USD | 20250228 | Open filing evidence |
| 2023-07-01 – 2023-09-30 | 0 | USD | 20241112 | Open filing evidence |
| 2023-01-01 – 2023-09-30 | 0 | USD | 20241112 | Open filing evidence |
US · Metabolic Disease Endocrine · Generics Segment
Statement Geographical · Product Or Service · Statement Business Segments
Source dimensions
srt:StatementGeographicalAxis=country:US;srt:ProductOrServiceAxis=amrx:MetabolicDiseaseEndocrineMember;us-gaap:StatementBusinessSegmentsAxis=amrx:GenericsSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2024-07-01 – 2024-09-30 | 8640000 | USD | 20241112 | Open filing evidence |
| 2024-01-01 – 2024-09-30 | 29298000 | USD | 20241112 | Open filing evidence |
| 2024-04-01 – 2024-06-30 | 9473000 | USD | 20240809 | Open filing evidence |
| 2024-01-01 – 2024-06-30 | 20658000 | USD | 20240809 | Open filing evidence |
| 2023-07-01 – 2023-09-30 | 11026000 | USD | 20241112 | Open filing evidence |
| 2023-01-01 – 2023-09-30 | 35227000 | USD | 20241112 | Open filing evidence |
US · Oncology · Generics Segment
Statement Geographical · Product Or Service · Statement Business Segments
Source dimensions
srt:StatementGeographicalAxis=country:US;srt:ProductOrServiceAxis=amrx:OncologyMember;us-gaap:StatementBusinessSegmentsAxis=amrx:GenericsSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2024-07-01 – 2024-09-30 | 44471000 | USD | 20241112 | Open filing evidence |
| 2024-01-01 – 2024-09-30 | 131270000 | USD | 20241112 | Open filing evidence |
| 2024-04-01 – 2024-06-30 | 48266000 | USD | 20240809 | Open filing evidence |
| 2024-01-01 – 2024-06-30 | 86799000 | USD | 20240809 | Open filing evidence |
| 2023-07-01 – 2023-09-30 | 37722000 | USD | 20241112 | Open filing evidence |
| 2023-01-01 – 2023-09-30 | 76846000 | USD | 20241112 | Open filing evidence |
US · Oral Liquid · Affordable Medicines Segment
Statement Geographical · Product Or Service · Statement Business Segments
Source dimensions
srt:StatementGeographicalAxis=country:US;srt:ProductOrServiceAxis=amrx:OralLiquidMember;us-gaap:StatementBusinessSegmentsAxis=amrx:AffordableMedicinesSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2025-01-01 – 2025-03-31 | 23548000 | USD | 20250507 | Open filing evidence |
| 2024-01-01 – 2024-12-31 | 103421000 | USD | 20250228 | Open filing evidence |
| 2024-01-01 – 2024-03-31 | 31929000 | USD | 20250507 | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 111045000 | USD | 20250228 | Open filing evidence |
US · Oral Solid · Affordable Medicines Segment
Statement Geographical · Product Or Service · Statement Business Segments
Source dimensions
srt:StatementGeographicalAxis=country:US;srt:ProductOrServiceAxis=amrx:OralSolidMember;us-gaap:StatementBusinessSegmentsAxis=amrx:AffordableMedicinesSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2025-01-01 – 2025-03-31 | 178953000 | USD | 20250507 | Open filing evidence |
| 2024-01-01 – 2024-12-31 | 689436000 | USD | 20250228 | Open filing evidence |
| 2024-01-01 – 2024-03-31 | 169313000 | USD | 20250507 | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 649998000 | USD | 20250228 | Open filing evidence |
US · Other Dosage Forms · Affordable Medicines Segment
Statement Geographical · Product Or Service · Statement Business Segments
Source dimensions
srt:StatementGeographicalAxis=country:US;srt:ProductOrServiceAxis=amrx:OtherDosageFormsMember;us-gaap:StatementBusinessSegmentsAxis=amrx:AffordableMedicinesSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2025-01-01 – 2025-03-31 | 56422000 | USD | 20250507 | Open filing evidence |
| 2024-01-01 – 2024-12-31 | 202188000 | USD | 20250228 | Open filing evidence |
| 2024-01-01 – 2024-03-31 | 43274000 | USD | 20250507 | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 180479000 | USD | 20250228 | Open filing evidence |
US · Other Therapeutic Classes · Generics Segment
Statement Geographical · Product Or Service · Statement Business Segments
Source dimensions
srt:StatementGeographicalAxis=country:US;srt:ProductOrServiceAxis=amrx:OtherTherapeuticClassesMember;us-gaap:StatementBusinessSegmentsAxis=amrx:GenericsSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2024-07-01 – 2024-09-30 | 38670000 | USD | 20241112 | Open filing evidence |
| 2024-01-01 – 2024-09-30 | 81263000 | USD | 20241112 | Open filing evidence |
| 2024-04-01 – 2024-06-30 | 24070000 | USD | 20240809 | Open filing evidence |
| 2024-01-01 – 2024-06-30 | 42593000 | USD | 20240809 | Open filing evidence |
| 2023-07-01 – 2023-09-30 | 27270000 | USD | 20241112 | Open filing evidence |
| 2023-01-01 – 2023-09-30 | 80974000 | USD | 20241112 | Open filing evidence |
US · Other Therapeutic Classes · Specialty Segment
Statement Geographical · Product Or Service · Statement Business Segments
Source dimensions
srt:StatementGeographicalAxis=country:US;srt:ProductOrServiceAxis=amrx:OtherTherapeuticClassesMember;us-gaap:StatementBusinessSegmentsAxis=amrx:SpecialtySegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2025-01-01 – 2025-03-31 | 6488000 | USD | 20250507 | Open filing evidence |
| 2024-01-01 – 2024-12-31 | 28622000 | USD | 20250228 | Open filing evidence |
| 2024-07-01 – 2024-09-30 | 7906000 | USD | 20241112 | Open filing evidence |
| 2024-01-01 – 2024-09-30 | 21370000 | USD | 20241112 | Open filing evidence |
| 2024-04-01 – 2024-06-30 | 8360000 | USD | 20240809 | Open filing evidence |
| 2024-01-01 – 2024-06-30 | 13464000 | USD | 20240809 | Open filing evidence |
| 2024-01-01 – 2024-03-31 | 5104000 | USD | 20250507 | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 29990000 | USD | 20250228 | Open filing evidence |
| 2023-07-01 – 2023-09-30 | 7668000 | USD | 20241112 | Open filing evidence |
| 2023-01-01 – 2023-09-30 | 22864000 | USD | 20241112 | Open filing evidence |
US · Respiratory · Generics Segment
Statement Geographical · Product Or Service · Statement Business Segments
Source dimensions
srt:StatementGeographicalAxis=country:US;srt:ProductOrServiceAxis=amrx:RespiratoryMember;us-gaap:StatementBusinessSegmentsAxis=amrx:GenericsSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2024-07-01 – 2024-09-30 | 9459000 | USD | 20241112 | Open filing evidence |
| 2024-01-01 – 2024-09-30 | 34002000 | USD | 20241112 | Open filing evidence |
| 2024-04-01 – 2024-06-30 | 13407000 | USD | 20240809 | Open filing evidence |
| 2024-01-01 – 2024-06-30 | 24543000 | USD | 20240809 | Open filing evidence |
| 2023-07-01 – 2023-09-30 | 7832000 | USD | 20241112 | Open filing evidence |
| 2023-01-01 – 2023-09-30 | 31783000 | USD | 20241112 | Open filing evidence |
US · Subtotal Dosage Forms · Affordable Medicines Segment
Statement Geographical · Product Or Service · Statement Business Segments
Source dimensions
srt:StatementGeographicalAxis=country:US;srt:ProductOrServiceAxis=amrx:SubtotalDosageFormsMember;us-gaap:StatementBusinessSegmentsAxis=amrx:AffordableMedicinesSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2025-01-01 – 2025-03-31 | 413474000 | USD | 20250507 | Open filing evidence |
| 2024-01-01 – 2024-12-31 | 1676311000 | USD | 20250228 | Open filing evidence |
| 2024-01-01 – 2024-03-31 | 389573000 | USD | 20250507 | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 1469236000 | USD | 20250228 | Open filing evidence |
US · Subtotal Therapeutic Classes · Specialty Segment
Statement Geographical · Product Or Service · Statement Business Segments
Source dimensions
srt:StatementGeographicalAxis=country:US;srt:ProductOrServiceAxis=amrx:SubtotalTherapeuticClassesMember;us-gaap:StatementBusinessSegmentsAxis=amrx:SpecialtySegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2025-01-01 – 2025-03-31 | 108297000 | USD | 20250507 | Open filing evidence |
| 2024-01-01 – 2024-12-31 | 439222000 | USD | 20250228 | Open filing evidence |
| 2024-01-01 – 2024-03-31 | 100755000 | USD | 20250507 | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 390457000 | USD | 20250228 | Open filing evidence |
US · Transdermal · Affordable Medicines Segment
Statement Geographical · Product Or Service · Statement Business Segments
Source dimensions
srt:StatementGeographicalAxis=country:US;srt:ProductOrServiceAxis=amrx:TransdermalMember;us-gaap:StatementBusinessSegmentsAxis=amrx:AffordableMedicinesSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2025-01-01 – 2025-03-31 | 43063000 | USD | 20250507 | Open filing evidence |
| 2024-01-01 – 2024-12-31 | 180917000 | USD | 20250228 | Open filing evidence |
| 2024-01-01 – 2024-03-31 | 40525000 | USD | 20250507 | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 159084000 | USD | 20250228 | Open filing evidence |
US · Distribution Service · Av KARE Segment
Statement Geographical · Product Or Service · Statement Business Segments
Source dimensions
srt:StatementGeographicalAxis=country:US;srt:ProductOrServiceAxis=us-gaap:DistributionServiceMember;us-gaap:StatementBusinessSegmentsAxis=amrx:AvKARESegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2025-01-01 – 2025-03-31 | 104895000 | USD | 20250507 | Open filing evidence |
| 2024-01-01 – 2024-12-31 | 433981000 | USD | 20250228 | Open filing evidence |
| 2024-07-01 – 2024-09-30 | 101605000 | USD | 20241112 | Open filing evidence |
| 2024-01-01 – 2024-09-30 | 327453000 | USD | 20241112 | Open filing evidence |
| 2024-04-01 – 2024-06-30 | 116135000 | USD | 20240809 | Open filing evidence |
| 2024-01-01 – 2024-06-30 | 225848000 | USD | 20240809 | Open filing evidence |
| 2024-01-01 – 2024-03-31 | 109713000 | USD | 20250507 | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 347406000 | USD | 20250228 | Open filing evidence |
| 2023-07-01 – 2023-09-30 | 81904000 | USD | 20241112 | Open filing evidence |
| 2023-01-01 – 2023-09-30 | 248929000 | USD | 20241112 | Open filing evidence |
US · Product And Service Other · Av KARE Segment
Statement Geographical · Product Or Service · Statement Business Segments
Source dimensions
srt:StatementGeographicalAxis=country:US;srt:ProductOrServiceAxis=us-gaap:ProductAndServiceOtherMember;us-gaap:StatementBusinessSegmentsAxis=amrx:AvKARESegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2025-01-01 – 2025-03-31 | 6371000 | USD | 20250507 | Open filing evidence |
| 2024-01-01 – 2024-12-31 | 26257000 | USD | 20250228 | Open filing evidence |
| 2024-07-01 – 2024-09-30 | 6550000 | USD | 20241112 | Open filing evidence |
| 2024-01-01 – 2024-09-30 | 19988000 | USD | 20241112 | Open filing evidence |
| 2024-04-01 – 2024-06-30 | 6298000 | USD | 20240809 | Open filing evidence |
| 2024-01-01 – 2024-06-30 | 13438000 | USD | 20240809 | Open filing evidence |
| 2024-01-01 – 2024-03-31 | 7140000 | USD | 20250507 | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 24498000 | USD | 20250228 | Open filing evidence |
| 2023-07-01 – 2023-09-30 | 6660000 | USD | 20241112 | Open filing evidence |
| 2023-01-01 – 2023-09-30 | 17812000 | USD | 20241112 | Open filing evidence |
US · Affordable Medicines Segment
Statement Geographical · Statement Business Segments
Source dimensions
srt:StatementGeographicalAxis=country:US;us-gaap:StatementBusinessSegmentsAxis=amrx:AffordableMedicinesSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2025-01-01 – 2025-12-31 | 1745524000 | USD | 20260227 | Open filing evidence |
| 2025-07-01 – 2025-09-30 | 460741000 | USD | 20251106 | Open filing evidence |
| 2025-01-01 – 2025-09-30 | 1308874000 | USD | 20251106 | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 433425000 | USD | 20250807 | Open filing evidence |
| 2025-01-01 – 2025-06-30 | 848133000 | USD | 20250807 | Open filing evidence |
| 2025-01-01 – 2025-03-31 | 414708000 | USD | 20250507 | Open filing evidence |
| 2024-01-01 – 2024-12-31 | 1685263000 | USD | 20260227 | Open filing evidence |
| 2024-07-01 – 2024-09-30 | 427345000 | USD | 20251106 | Open filing evidence |
| 2024-01-01 – 2024-09-30 | 1245967000 | USD | 20251106 | Open filing evidence |
| 2024-04-01 – 2024-06-30 | 427328000 | USD | 20250807 | Open filing evidence |
| 2024-01-01 – 2024-06-30 | 818622000 | USD | 20250807 | Open filing evidence |
| 2024-01-01 – 2024-03-31 | 391294000 | USD | 20250507 | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 1471401000 | USD | 20260227 | Open filing evidence |
US · Av KARE Segment · Government Label
Statement Geographical · Statement Business Segments · Product Or Service
Source dimensions
srt:StatementGeographicalAxis=country:US;us-gaap:StatementBusinessSegmentsAxis=amrx:AvKARESegmentMember;srt:ProductOrServiceAxis=amrx:GovernmentLabelMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2023-01-01 – 2023-12-31 | 121829000 | USD | 20240314 | Open filing evidence |
US · Generics Segment · Anti Infective
Statement Geographical · Statement Business Segments · Product Or Service
Source dimensions
srt:StatementGeographicalAxis=country:US;us-gaap:StatementBusinessSegmentsAxis=amrx:GenericsSegmentMember;srt:ProductOrServiceAxis=amrx:AntiInfectiveMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2024-01-01 – 2024-03-31 | 6110000 | USD | 20240508 | Open filing evidence |
US · Generics Segment · Antiviral
Statement Geographical · Statement Business Segments · Product Or Service
Source dimensions
srt:StatementGeographicalAxis=country:US;us-gaap:StatementBusinessSegmentsAxis=amrx:GenericsSegmentMember;srt:ProductOrServiceAxis=amrx:AntiviralMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2024-01-01 – 2024-03-31 | 3866000 | USD | 20240508 | Open filing evidence |
US · Generics Segment · Central Nervous System
Statement Geographical · Statement Business Segments · Product Or Service
Source dimensions
srt:StatementGeographicalAxis=country:US;us-gaap:StatementBusinessSegmentsAxis=amrx:GenericsSegmentMember;srt:ProductOrServiceAxis=amrx:CentralNervousSystemMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2024-01-01 – 2024-03-31 | 109456000 | USD | 20240508 | Open filing evidence |
US · Generics Segment · Dermatology
Statement Geographical · Statement Business Segments · Product Or Service
Source dimensions
srt:StatementGeographicalAxis=country:US;us-gaap:StatementBusinessSegmentsAxis=amrx:GenericsSegmentMember;srt:ProductOrServiceAxis=amrx:DermatologyMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2024-01-01 – 2024-03-31 | 18975000 | USD | 20240508 | Open filing evidence |
US · Generics Segment · Other Therapeutic Classes
Statement Geographical · Statement Business Segments · Product Or Service
Source dimensions
srt:StatementGeographicalAxis=country:US;us-gaap:StatementBusinessSegmentsAxis=amrx:GenericsSegmentMember;srt:ProductOrServiceAxis=amrx:OtherTherapeuticClassesMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2024-01-01 – 2024-03-31 | 18523000 | USD | 20240508 | Open filing evidence |
US · Generics Segment · Respiratory
Statement Geographical · Statement Business Segments · Product Or Service
Source dimensions
srt:StatementGeographicalAxis=country:US;us-gaap:StatementBusinessSegmentsAxis=amrx:GenericsSegmentMember;srt:ProductOrServiceAxis=amrx:RespiratoryMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2024-01-01 – 2024-03-31 | 11136000 | USD | 20240508 | Open filing evidence |
Non Us · Generics Segment
Statement Geographical · Statement Business Segments
Source dimensions
srt:StatementGeographicalAxis=us-gaap:NonUsMember;us-gaap:StatementBusinessSegmentsAxis=amrx:GenericsSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2024-07-01 – 2024-09-30 | 4508000 | USD | 20241112 | Open filing evidence |
| 2024-01-01 – 2024-09-30 | 7659000 | USD | 20241112 | Open filing evidence |
| 2024-04-01 – 2024-06-30 | 1430000 | USD | 20240809 | Open filing evidence |
| 2024-01-01 – 2024-06-30 | 3151000 | USD | 20240809 | Open filing evidence |
| 2024-01-01 – 2024-03-31 | 1721000 | USD | 20240508 | Open filing evidence |
| 2023-07-01 – 2023-09-30 | 867000 | USD | 20241112 | Open filing evidence |
| 2023-01-01 – 2023-09-30 | 1714000 | USD | 20241112 | Open filing evidence |
Affordable Medicines Segment
Statement Business Segments
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=amrx:AffordableMedicinesSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-07-01 – 2026-09-30 | 547109000 | USD | 20261109 | Open filing evidence |
| 2026-01-01 – 2026-09-30 | 1460259000 | USD | 20261109 | Open filing evidence |
| 2026-04-01 – 2026-06-30 | 489913000 | USD | 20260806 | Open filing evidence |
| 2026-01-01 – 2026-06-30 | 913150000 | USD | 20260806 | Open filing evidence |
| 2026-01-01 – 2026-03-31 | 423237000 | USD | 20260507 | Open filing evidence |
| 2025-07-01 – 2025-09-30 | 460741000 | USD | 20261109 | Open filing evidence |
| 2025-01-01 – 2025-09-30 | 1308874000 | USD | 20261109 | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 433425000 | USD | 20260806 | Open filing evidence |
| 2025-01-01 – 2025-06-30 | 848133000 | USD | 20260806 | Open filing evidence |
| 2025-01-01 – 2025-03-31 | 414708000 | USD | 20260507 | Open filing evidence |
Affordable Medicines Segment · Operating Segments
Statement Business Segments · Consolidation Items
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=amrx:AffordableMedicinesSegmentMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-07-01 – 2026-09-30 | 547109000 | USD | 20261109 | Open filing evidence |
| 2026-01-01 – 2026-09-30 | 1460259000 | USD | 20261109 | Open filing evidence |
| 2025-07-01 – 2025-09-30 | 460741000 | USD | 20261109 | Open filing evidence |
| 2025-01-01 – 2025-09-30 | 1308874000 | USD | 20261109 | Open filing evidence |
Affordable Medicines Segment · Biosimilar
Statement Business Segments · Product Or Service
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=amrx:AffordableMedicinesSegmentMember;srt:ProductOrServiceAxis=amrx:BiosimilarMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-07-01 – 2026-09-30 | 77710000 | USD | 20261109 | Open filing evidence |
| 2026-01-01 – 2026-09-30 | 129139000 | USD | 20261109 | Open filing evidence |
| 2025-07-01 – 2025-09-30 | 17009000 | USD | 20261109 | Open filing evidence |
| 2025-01-01 – 2025-09-30 | 70797000 | USD | 20261109 | Open filing evidence |
Affordable Medicines Segment · Ephinephrine Auto Injector
Statement Business Segments · Product Or Service
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=amrx:AffordableMedicinesSegmentMember;srt:ProductOrServiceAxis=amrx:EphinephrineAutoInjectorMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-07-01 – 2026-09-30 | 65163000 | USD | 20261109 | Open filing evidence |
| 2026-01-01 – 2026-09-30 | 169289000 | USD | 20261109 | Open filing evidence |
| 2025-07-01 – 2025-09-30 | 78940000 | USD | 20261109 | Open filing evidence |
| 2025-01-01 – 2025-09-30 | 193694000 | USD | 20261109 | Open filing evidence |
Affordable Medicines Segment · Injectable
Statement Business Segments · Product Or Service
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=amrx:AffordableMedicinesSegmentMember;srt:ProductOrServiceAxis=amrx:InjectableMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-07-01 – 2026-09-30 | 53805000 | USD | 20261109 | Open filing evidence |
| 2026-01-01 – 2026-09-30 | 160526000 | USD | 20261109 | Open filing evidence |
| 2025-07-01 – 2025-09-30 | 54368000 | USD | 20261109 | Open filing evidence |
| 2025-01-01 – 2025-09-30 | 123802000 | USD | 20261109 | Open filing evidence |
Affordable Medicines Segment · International
Statement Business Segments · Product Or Service
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=amrx:AffordableMedicinesSegmentMember;srt:ProductOrServiceAxis=amrx:InternationalMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-07-01 – 2026-09-30 | 4915000 | USD | 20261109 | Open filing evidence |
| 2026-01-01 – 2026-09-30 | 17847000 | USD | 20261109 | Open filing evidence |
| 2025-07-01 – 2025-09-30 | 6288000 | USD | 20261109 | Open filing evidence |
| 2025-01-01 – 2025-09-30 | 9423000 | USD | 20261109 | Open filing evidence |
Affordable Medicines Segment · Oral Liquid
Statement Business Segments · Product Or Service
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=amrx:AffordableMedicinesSegmentMember;srt:ProductOrServiceAxis=amrx:OralLiquidMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-07-01 – 2026-09-30 | 9092000 | USD | 20261109 | Open filing evidence |
| 2026-01-01 – 2026-09-30 | 31555000 | USD | 20261109 | Open filing evidence |
| 2025-07-01 – 2025-09-30 | 16415000 | USD | 20261109 | Open filing evidence |
| 2025-01-01 – 2025-09-30 | 57842000 | USD | 20261109 | Open filing evidence |
Affordable Medicines Segment · Oral Solid
Statement Business Segments · Product Or Service
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=amrx:AffordableMedicinesSegmentMember;srt:ProductOrServiceAxis=amrx:OralSolidMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-07-01 – 2026-09-30 | 207517000 | USD | 20261109 | Open filing evidence |
| 2026-01-01 – 2026-09-30 | 553789000 | USD | 20261109 | Open filing evidence |
| 2025-07-01 – 2025-09-30 | 180460000 | USD | 20261109 | Open filing evidence |
| 2025-01-01 – 2025-09-30 | 537675000 | USD | 20261109 | Open filing evidence |
Affordable Medicines Segment · Other Dosage Forms
Statement Business Segments · Product Or Service
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=amrx:AffordableMedicinesSegmentMember;srt:ProductOrServiceAxis=amrx:OtherDosageFormsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-07-01 – 2026-09-30 | 60841000 | USD | 20261109 | Open filing evidence |
| 2026-01-01 – 2026-09-30 | 189047000 | USD | 20261109 | Open filing evidence |
| 2025-07-01 – 2025-09-30 | 59662000 | USD | 20261109 | Open filing evidence |
| 2025-01-01 – 2025-09-30 | 184269000 | USD | 20261109 | Open filing evidence |
Affordable Medicines Segment · Subtotal Dosage Forms
Statement Business Segments · Product Or Service
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=amrx:AffordableMedicinesSegmentMember;srt:ProductOrServiceAxis=amrx:SubtotalDosageFormsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-07-01 – 2026-09-30 | 542194000 | USD | 20261109 | Open filing evidence |
| 2026-01-01 – 2026-09-30 | 1442412000 | USD | 20261109 | Open filing evidence |
| 2025-07-01 – 2025-09-30 | 454453000 | USD | 20261109 | Open filing evidence |
| 2025-01-01 – 2025-09-30 | 1299451000 | USD | 20261109 | Open filing evidence |
Affordable Medicines Segment · Transdermal
Statement Business Segments · Product Or Service
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=amrx:AffordableMedicinesSegmentMember;srt:ProductOrServiceAxis=amrx:TransdermalMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-07-01 – 2026-09-30 | 68066000 | USD | 20261109 | Open filing evidence |
| 2026-01-01 – 2026-09-30 | 209067000 | USD | 20261109 | Open filing evidence |
| 2025-07-01 – 2025-09-30 | 47599000 | USD | 20261109 | Open filing evidence |
| 2025-01-01 – 2025-09-30 | 131372000 | USD | 20261109 | Open filing evidence |
Amneal Specialty Pharma Segment · Operating Segments
Statement Business Segments · Consolidation Items
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=amrx:AmnealSpecialtyPharmaSegmentMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-07-01 – 2026-09-30 | 150262000 | USD | 20261109 | Open filing evidence |
| 2026-01-01 – 2026-09-30 | 432822000 | USD | 20261109 | Open filing evidence |
| 2025-07-01 – 2025-09-30 | 125240000 | USD | 20261109 | Open filing evidence |
| 2025-01-01 – 2025-09-30 | 361580000 | USD | 20261109 | Open filing evidence |
| 2023-07-01 – 2023-09-30 | 97304000 | USD | 20231109 | Open filing evidence |
| 2023-01-01 – 2023-09-30 | 285976000 | USD | 20231109 | Open filing evidence |
Av KARE Segment
Statement Business Segments
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=amrx:AvKARESegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-07-01 – 2026-09-30 | 165313000 | USD | 20261109 | Open filing evidence |
| 2026-01-01 – 2026-09-30 | 488319000 | USD | 20261109 | Open filing evidence |
| 2026-04-01 – 2026-06-30 | 156989000 | USD | 20260806 | Open filing evidence |
| 2026-01-01 – 2026-06-30 | 323006000 | USD | 20260806 | Open filing evidence |
| 2026-01-01 – 2026-03-31 | 166017000 | USD | 20260507 | Open filing evidence |
| 2025-01-01 – 2025-12-31 | 744728000 | USD | 20260227 | Open filing evidence |
| 2025-07-01 – 2025-09-30 | 198532000 | USD | 20261109 | Open filing evidence |
| 2025-01-01 – 2025-09-30 | 533987000 | USD | 20261109 | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 163040000 | USD | 20260806 | Open filing evidence |
| 2025-01-01 – 2025-06-30 | 335455000 | USD | 20260806 | Open filing evidence |
| 2025-01-01 – 2025-03-31 | 172415000 | USD | 20260507 | Open filing evidence |
| 2024-01-01 – 2024-12-31 | 662945000 | USD | 20260227 | Open filing evidence |
| 2024-07-01 – 2024-09-30 | 159485000 | USD | 20251106 | Open filing evidence |
| 2024-01-01 – 2024-09-30 | 492559000 | USD | 20251106 | Open filing evidence |
| 2024-04-01 – 2024-06-30 | 170411000 | USD | 20250807 | Open filing evidence |
| 2024-01-01 – 2024-06-30 | 333074000 | USD | 20250807 | Open filing evidence |
| 2024-01-01 – 2024-03-31 | 162663000 | USD | 20250507 | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 531749000 | USD | 20260227 | Open filing evidence |
| 2023-07-01 – 2023-09-30 | 131879000 | USD | 20241112 | Open filing evidence |
| 2023-01-01 – 2023-09-30 | 382286000 | USD | 20241112 | Open filing evidence |
Av KARE Segment · Operating Segments
Statement Business Segments · Consolidation Items
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=amrx:AvKARESegmentMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-07-01 – 2026-09-30 | 165313000 | USD | 20261109 | Open filing evidence |
| 2026-01-01 – 2026-09-30 | 488319000 | USD | 20261109 | Open filing evidence |
| 2025-07-01 – 2025-09-30 | 198532000 | USD | 20261109 | Open filing evidence |
| 2025-01-01 – 2025-09-30 | 533987000 | USD | 20261109 | Open filing evidence |
Av KARE Segment · Government Label
Statement Business Segments · Product Or Service
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=amrx:AvKARESegmentMember;srt:ProductOrServiceAxis=amrx:GovernmentLabelMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-07-01 – 2026-09-30 | 53385000 | USD | 20261109 | Open filing evidence |
| 2026-01-01 – 2026-09-30 | 163541000 | USD | 20261109 | Open filing evidence |
| 2025-07-01 – 2025-09-30 | 87755000 | USD | 20261109 | Open filing evidence |
| 2025-01-01 – 2025-09-30 | 183313000 | USD | 20261109 | Open filing evidence |
Av KARE Segment · Institutional
Statement Business Segments · Product Or Service
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=amrx:AvKARESegmentMember;srt:ProductOrServiceAxis=amrx:InstitutionalMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-07-01 – 2026-09-30 | 10012000 | USD | 20261109 | Open filing evidence |
| 2026-01-01 – 2026-09-30 | 31943000 | USD | 20261109 | Open filing evidence |
| 2025-07-01 – 2025-09-30 | 5853000 | USD | 20261109 | Open filing evidence |
| 2025-01-01 – 2025-09-30 | 26994000 | USD | 20261109 | Open filing evidence |
Av KARE Segment · Distribution Service
Statement Business Segments · Product Or Service
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=amrx:AvKARESegmentMember;srt:ProductOrServiceAxis=us-gaap:DistributionServiceMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-07-01 – 2026-09-30 | 92905000 | USD | 20261109 | Open filing evidence |
| 2026-01-01 – 2026-09-30 | 268984000 | USD | 20261109 | Open filing evidence |
| 2025-07-01 – 2025-09-30 | 96216000 | USD | 20261109 | Open filing evidence |
| 2025-01-01 – 2025-09-30 | 300774000 | USD | 20261109 | Open filing evidence |
Av KARE Segment · Distribution Service · US
Statement Business Segments · Product Or Service · Statement Geographical
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=amrx:AvKARESegmentMember;srt:ProductOrServiceAxis=us-gaap:DistributionServiceMember;srt:StatementGeographicalAxis=country:US| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2023-07-01 – 2023-09-30 | 81904000 | USD | 20231109 | Open filing evidence |
| 2023-01-01 – 2023-09-30 | 248929000 | USD | 20231109 | Open filing evidence |
Av KARE Segment · Product And Service Other
Statement Business Segments · Product Or Service
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=amrx:AvKARESegmentMember;srt:ProductOrServiceAxis=us-gaap:ProductAndServiceOtherMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-07-01 – 2026-09-30 | 9011000 | USD | 20261109 | Open filing evidence |
| 2026-01-01 – 2026-09-30 | 23851000 | USD | 20261109 | Open filing evidence |
| 2025-07-01 – 2025-09-30 | 8708000 | USD | 20261109 | Open filing evidence |
| 2025-01-01 – 2025-09-30 | 22906000 | USD | 20261109 | Open filing evidence |
Av KARE Segment · Product And Service Other · US
Statement Business Segments · Product Or Service · Statement Geographical
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=amrx:AvKARESegmentMember;srt:ProductOrServiceAxis=us-gaap:ProductAndServiceOtherMember;srt:StatementGeographicalAxis=country:US| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2023-07-01 – 2023-09-30 | 6660000 | USD | 20231109 | Open filing evidence |
| 2023-01-01 – 2023-09-30 | 17812000 | USD | 20231109 | Open filing evidence |
Generics Segment
Statement Business Segments
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=amrx:GenericsSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2024-07-01 – 2024-09-30 | 427345000 | USD | 20241112 | Open filing evidence |
| 2024-01-01 – 2024-09-30 | 1245967000 | USD | 20241112 | Open filing evidence |
| 2024-04-01 – 2024-06-30 | 427328000 | USD | 20240809 | Open filing evidence |
| 2024-01-01 – 2024-06-30 | 818622000 | USD | 20240809 | Open filing evidence |
| 2024-01-01 – 2024-03-31 | 391294000 | USD | 20240508 | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 1471401000 | USD | 20240314 | Open filing evidence |
| 2023-07-01 – 2023-09-30 | 390857000 | USD | 20241112 | Open filing evidence |
| 2023-01-01 – 2023-09-30 | 1108364000 | USD | 20241112 | Open filing evidence |
Generics Segment · Operating Segments
Statement Business Segments · Consolidation Items
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=amrx:GenericsSegmentMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2023-01-01 – 2023-12-31 | 1471401000 | USD | 20240314 | Open filing evidence |
| 2023-07-01 – 2023-09-30 | 390857000 | USD | 20231109 | Open filing evidence |
| 2023-01-01 – 2023-09-30 | 1108364000 | USD | 20231109 | Open filing evidence |
Generics Segment · Anti Infective · US
Statement Business Segments · Product Or Service · Statement Geographical
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=amrx:GenericsSegmentMember;srt:ProductOrServiceAxis=amrx:AntiInfectiveMember;srt:StatementGeographicalAxis=country:US| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2023-01-01 – 2023-12-31 | 25885000 | USD | 20240314 | Open filing evidence |
Generics Segment · Antiviral · US
Statement Business Segments · Product Or Service · Statement Geographical
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=amrx:GenericsSegmentMember;srt:ProductOrServiceAxis=amrx:AntiviralMember;srt:StatementGeographicalAxis=country:US| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2023-01-01 – 2023-12-31 | 39910000 | USD | 20240314 | Open filing evidence |
Generics Segment · Cardiovascular System · US
Statement Business Segments · Product Or Service · Statement Geographical
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=amrx:GenericsSegmentMember;srt:ProductOrServiceAxis=amrx:CardiovascularSystemMember;srt:StatementGeographicalAxis=country:US| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2023-01-01 – 2023-12-31 | 139942000 | USD | 20240314 | Open filing evidence |
Generics Segment · Dermatology · US
Statement Business Segments · Product Or Service · Statement Geographical
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=amrx:GenericsSegmentMember;srt:ProductOrServiceAxis=amrx:DermatologyMember;srt:StatementGeographicalAxis=country:US| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2023-01-01 – 2023-12-31 | 70872000 | USD | 20240314 | Open filing evidence |
| 2023-07-01 – 2023-09-30 | 17279000 | USD | 20231109 | Open filing evidence |
| 2023-01-01 – 2023-09-30 | 53232000 | USD | 20231109 | Open filing evidence |
Generics Segment · Gastroenterology · US
Statement Business Segments · Product Or Service · Statement Geographical
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=amrx:GenericsSegmentMember;srt:ProductOrServiceAxis=amrx:GastroenterologyMember;srt:StatementGeographicalAxis=country:US| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2023-01-01 – 2023-12-31 | 67519000 | USD | 20240314 | Open filing evidence |
| 2023-07-01 – 2023-09-30 | 18858000 | USD | 20231109 | Open filing evidence |
| 2023-01-01 – 2023-09-30 | 53127000 | USD | 20231109 | Open filing evidence |
Generics Segment · Hormonal Allergy · US
Statement Business Segments · Product Or Service · Statement Geographical
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=amrx:GenericsSegmentMember;srt:ProductOrServiceAxis=amrx:HormonalAllergyMember;srt:StatementGeographicalAxis=country:US| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2023-07-01 – 2023-09-30 | 126425000 | USD | 20231109 | Open filing evidence |
| 2023-01-01 – 2023-09-30 | 357711000 | USD | 20231109 | Open filing evidence |
Generics Segment · License Agreement · US
Statement Business Segments · Product Or Service · Statement Geographical
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=amrx:GenericsSegmentMember;srt:ProductOrServiceAxis=amrx:LicenseAgreementMember;srt:StatementGeographicalAxis=country:US| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2023-01-01 – 2023-12-31 | 0 | USD | 20240314 | Open filing evidence |
Generics Segment · Metabolic Disease Endocrine · US
Statement Business Segments · Product Or Service · Statement Geographical
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=amrx:GenericsSegmentMember;srt:ProductOrServiceAxis=amrx:MetabolicDiseaseEndocrineMember;srt:StatementGeographicalAxis=country:US| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2023-07-01 – 2023-09-30 | 11026000 | USD | 20231109 | Open filing evidence |
| 2023-01-01 – 2023-09-30 | 35227000 | USD | 20231109 | Open filing evidence |
Generics Segment · Other Therapeutic Classes · US
Statement Business Segments · Product Or Service · Statement Geographical
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=amrx:GenericsSegmentMember;srt:ProductOrServiceAxis=amrx:OtherTherapeuticClassesMember;srt:StatementGeographicalAxis=country:US| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2023-01-01 – 2023-12-31 | 105106000 | USD | 20240314 | Open filing evidence |
Generics Segment · Respiratory · US
Statement Business Segments · Product Or Service · Statement Geographical
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=amrx:GenericsSegmentMember;srt:ProductOrServiceAxis=amrx:RespiratoryMember;srt:StatementGeographicalAxis=country:US| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2023-07-01 – 2023-09-30 | 7832000 | USD | 20231109 | Open filing evidence |
| 2023-01-01 – 2023-09-30 | 31783000 | USD | 20231109 | Open filing evidence |
Generics Segment · US · Anti Infective
Statement Business Segments · Statement Geographical · Product Or Service
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=amrx:GenericsSegmentMember;srt:StatementGeographicalAxis=country:US;srt:ProductOrServiceAxis=amrx:AntiInfectiveMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2023-07-01 – 2023-09-30 | 7382000 | USD | 20231109 | Open filing evidence |
| 2023-01-01 – 2023-09-30 | 18648000 | USD | 20231109 | Open filing evidence |
Generics Segment · US · Central Nervous System
Statement Business Segments · Statement Geographical · Product Or Service
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=amrx:GenericsSegmentMember;srt:StatementGeographicalAxis=country:US;srt:ProductOrServiceAxis=amrx:CentralNervousSystemMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2023-01-01 – 2023-12-31 | 369201000 | USD | 20240314 | Open filing evidence |
| 2023-07-01 – 2023-09-30 | 96587000 | USD | 20231109 | Open filing evidence |
| 2023-01-01 – 2023-09-30 | 264773000 | USD | 20231109 | Open filing evidence |
Generics Segment · US · Hormonal Allergy
Statement Business Segments · Statement Geographical · Product Or Service
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=amrx:GenericsSegmentMember;srt:StatementGeographicalAxis=country:US;srt:ProductOrServiceAxis=amrx:HormonalAllergyMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2023-01-01 – 2023-12-31 | 451736000 | USD | 20240314 | Open filing evidence |
Generics Segment · US · Metabolic Disease Endocrine
Statement Business Segments · Statement Geographical · Product Or Service
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=amrx:GenericsSegmentMember;srt:StatementGeographicalAxis=country:US;srt:ProductOrServiceAxis=amrx:MetabolicDiseaseEndocrineMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2023-01-01 – 2023-12-31 | 45900000 | USD | 20240314 | Open filing evidence |
Generics Segment · US · Oncology
Statement Business Segments · Statement Geographical · Product Or Service
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=amrx:GenericsSegmentMember;srt:StatementGeographicalAxis=country:US;srt:ProductOrServiceAxis=amrx:OncologyMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2023-01-01 – 2023-12-31 | 110455000 | USD | 20240314 | Open filing evidence |
Generics Segment · US · Respiratory
Statement Business Segments · Statement Geographical · Product Or Service
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=amrx:GenericsSegmentMember;srt:StatementGeographicalAxis=country:US;srt:ProductOrServiceAxis=amrx:RespiratoryMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2023-01-01 – 2023-12-31 | 42710000 | USD | 20240314 | Open filing evidence |
Generics Segment · Non Us
Statement Business Segments · Statement Geographical
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=amrx:GenericsSegmentMember;srt:StatementGeographicalAxis=us-gaap:NonUsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2023-01-01 – 2023-12-31 | 2165000 | USD | 20240314 | Open filing evidence |
Specialty Segment
Statement Business Segments
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=amrx:SpecialtySegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-07-01 – 2026-09-30 | 150262000 | USD | 20261109 | Open filing evidence |
| 2026-01-01 – 2026-09-30 | 432822000 | USD | 20261109 | Open filing evidence |
| 2026-04-01 – 2026-06-30 | 149295000 | USD | 20260806 | Open filing evidence |
| 2026-01-01 – 2026-06-30 | 282560000 | USD | 20260806 | Open filing evidence |
| 2025-01-01 – 2025-12-31 | 528508000 | USD | 20260227 | Open filing evidence |
| 2025-07-01 – 2025-09-30 | 125240000 | USD | 20261109 | Open filing evidence |
| 2025-01-01 – 2025-09-30 | 361580000 | USD | 20261109 | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 128043000 | USD | 20260806 | Open filing evidence |
| 2025-01-01 – 2025-06-30 | 236340000 | USD | 20260806 | Open filing evidence |
| 2025-01-01 – 2025-03-31 | 108297000 | USD | 20250507 | Open filing evidence |
| 2024-01-01 – 2024-12-31 | 445749000 | USD | 20260227 | Open filing evidence |
| 2024-07-01 – 2024-09-30 | 115638000 | USD | 20251106 | Open filing evidence |
| 2024-01-01 – 2024-09-30 | 324913000 | USD | 20251106 | Open filing evidence |
| 2024-04-01 – 2024-06-30 | 104041000 | USD | 20250807 | Open filing evidence |
| 2024-01-01 – 2024-06-30 | 209275000 | USD | 20250807 | Open filing evidence |
| 2024-01-01 – 2024-03-31 | 105234000 | USD | 20250507 | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 390457000 | USD | 20260227 | Open filing evidence |
| 2023-07-01 – 2023-09-30 | 97304000 | USD | 20241112 | Open filing evidence |
| 2023-01-01 – 2023-09-30 | 285976000 | USD | 20241112 | Open filing evidence |
Specialty Segment · Operating Segments
Statement Business Segments · Consolidation Items
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=amrx:SpecialtySegmentMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2023-01-01 – 2023-12-31 | 390457000 | USD | 20240314 | Open filing evidence |
Specialty Segment · Central Nervous System
Statement Business Segments · Product Or Service
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=amrx:SpecialtySegmentMember;srt:ProductOrServiceAxis=amrx:CentralNervousSystemMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-07-01 – 2026-09-30 | 96177000 | USD | 20261109 | Open filing evidence |
| 2026-01-01 – 2026-09-30 | 274904000 | USD | 20261109 | Open filing evidence |
| 2025-07-01 – 2025-09-30 | 77631000 | USD | 20261109 | Open filing evidence |
| 2025-01-01 – 2025-09-30 | 228666000 | USD | 20261109 | Open filing evidence |
Specialty Segment · Hormonal Allergy
Statement Business Segments · Product Or Service
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=amrx:SpecialtySegmentMember;srt:ProductOrServiceAxis=amrx:HormonalAllergyMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-07-01 – 2026-09-30 | 43148000 | USD | 20261109 | Open filing evidence |
| 2026-01-01 – 2026-09-30 | 121179000 | USD | 20261109 | Open filing evidence |
| 2025-07-01 – 2025-09-30 | 37685000 | USD | 20261109 | Open filing evidence |
| 2025-01-01 – 2025-09-30 | 107302000 | USD | 20261109 | Open filing evidence |
Specialty Segment · Hormonal Allergy · US
Statement Business Segments · Product Or Service · Statement Geographical
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=amrx:SpecialtySegmentMember;srt:ProductOrServiceAxis=amrx:HormonalAllergyMember;srt:StatementGeographicalAxis=country:US| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2023-01-01 – 2023-09-30 | 82268000 | USD | 20231109 | Open filing evidence |
Specialty Segment · License Agreement
Statement Business Segments · Product Or Service
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=amrx:SpecialtySegmentMember;srt:ProductOrServiceAxis=amrx:LicenseAgreementMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-07-01 – 2026-09-30 | 1488000 | USD | 20261109 | Open filing evidence |
| 2026-01-01 – 2026-09-30 | 1488000 | USD | 20261109 | Open filing evidence |
| 2025-07-01 – 2025-09-30 | 0 | USD | 20261109 | Open filing evidence |
| 2025-01-01 – 2025-09-30 | 500000 | USD | 20261109 | Open filing evidence |
Specialty Segment · Other Therapeutic Classes
Statement Business Segments · Product Or Service
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=amrx:SpecialtySegmentMember;srt:ProductOrServiceAxis=amrx:OtherTherapeuticClassesMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-07-01 – 2026-09-30 | 9449000 | USD | 20261109 | Open filing evidence |
| 2026-01-01 – 2026-09-30 | 35251000 | USD | 20261109 | Open filing evidence |
| 2025-07-01 – 2025-09-30 | 9924000 | USD | 20261109 | Open filing evidence |
| 2025-01-01 – 2025-09-30 | 25112000 | USD | 20261109 | Open filing evidence |
Specialty Segment · Subtotal Therapeutic Classes
Statement Business Segments · Product Or Service
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=amrx:SpecialtySegmentMember;srt:ProductOrServiceAxis=amrx:SubtotalTherapeuticClassesMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-07-01 – 2026-09-30 | 148774000 | USD | 20261109 | Open filing evidence |
| 2026-01-01 – 2026-09-30 | 431334000 | USD | 20261109 | Open filing evidence |
| 2025-07-01 – 2025-09-30 | 125240000 | USD | 20261109 | Open filing evidence |
| 2025-01-01 – 2025-09-30 | 361080000 | USD | 20261109 | Open filing evidence |
Specialty Segment · US · Central Nervous System
Statement Business Segments · Statement Geographical · Product Or Service
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=amrx:SpecialtySegmentMember;srt:StatementGeographicalAxis=country:US;srt:ProductOrServiceAxis=amrx:CentralNervousSystemMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2023-01-01 – 2023-12-31 | 249981000 | USD | 20240314 | Open filing evidence |
Specialty Segment · US · Hormonal Allergy
Statement Business Segments · Statement Geographical · Product Or Service
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=amrx:SpecialtySegmentMember;srt:StatementGeographicalAxis=country:US;srt:ProductOrServiceAxis=amrx:HormonalAllergyMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2023-01-01 – 2023-12-31 | 110486000 | USD | 20240314 | Open filing evidence |